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ABSTRACT
The aim of this study was to evaluate two enzyme immunoassays for the 
estimation of serum and salivary digoxin. The methods under review 
were the Enzyme Multiplied Immunoassay Technique and Cloned Enzyme 
Donor Immunoassay assays. Within and between assay precision for both 
immunoassays was good giving co-efficient of variations of less than 
6.1%. Analytical recoveries ranged from 96-103%. Sensitivity was 
0.28 nmol/1 of digoxin, approximately. Results from serum specimens 
from 52 patients using both methods and a RIA method from an external 
laboratory (Beaumont Hospital) were compared. A correlation of 1.008 
was obtained for the EMIT and RIA methods, while 0.985 resulted from 
the EMIT and CEDIA methods. The RIA and CEDIA methods gave a 
correlation of 0.94. Haemoglobin, bilirubin, lipaemia, and matrix 
effects, i.e. (protein concentration) did not interfere with the 
estimation of digoxin by the EMIT method. In the CEDIA method, high 
concentrations of protein resulted in falsely low digoxin 
concentrations, whereas low protein concentrations gave falsely high 
digoxin concentrations. Haemoglobin, bilirubin, and lipaemia caused 
interferences with the assay which was concentration dependent. 
Digoxin-like Immunoreactive Factors were greatly reduced or 
eliminated by the EMIT technique but interfered with the CEDIA method 
resulting in "apparent digoxin concentrations" as high as 1.18 
nmol/1.
A further study was performed to investigate the possible use of the 
EMIT and CEDIA methods for salivary digoxin estimations. Accuracy, 
precision, sensitivity and linearity were found to be comparable with 
that of the serum digoxin methods. No procedural modification was 
required for the EMIT method, while minor modifications were needed 
for the CEDIA.
The mean digoxin saliva/serum concentration ratio in 20 hospital 
patients using the EMIT method was 0.67 and the correlation was 0.96. 
The mean ratio using the CEDIA method was 0.62 with a correlation of 
0.93. These results were obtained when serum and saliva samples were 
taken simultaneously. In each method, DLIF concentration less than 
the sensitivity range was obtained in saliva from patients in renal 
and hepatic failure and third trimester pregnancy.
On the basis of all the factors assessed, the EMIT is the most 
suitable for routine use in the clinical chemistry laboratory.
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PART 1
Chapter 1
INTRODUCTION
Digoxin is an orally administered cardioactive drug used in the 
treatment of chronic heart disease. Its rapid absorption and 
elimination makes it clinically desirable. However, the
pharmacokinetics of the drug may also cause over-digitilization 
necessitating immediate diagnosis and treatment.
Various assay methods have been developed for serum digoxin 
estimation and are now in routine use in most clinical chemistry 
laboratories. Two enzyme immunoassays, CEDIA and EMIT were evaluated 
in this study. Since the concentration of certain drugs in saliva is 
related to their concentration in plasma it was decided to evaluate 
both assays for the measurement of salivary digoxin. Such a method 
offers a non-invasive alternative to the direct measurement of plasma 
digoxin concentrations.
From the literature search which forms Part 1 of this thesis, there 
are no reports of comparability studies involving these two assays. 
Part 2 consists of research work involved in the evaluation of the 
EMIT and CEDIA methods for digoxin measurement.
In order to appreciate fully the value of digoxin monitoring and the 
principles of cardiac glycoside therapy, a basic understanding of the 
anatomy, physiology and pathology of the human heart is essential.
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1.1 ANATOMY:
(a) GENERAL:
The heart acts as the pump for the circulatory blood system. Figure 
1 shows the heart, nervous control system, and the circulatory 
system. It lies in the thorax behind the sternum with its apex on 
the diaphragm extending to the left for three and a half inches 
[1-4].
The heart is surrounded by the pericardium which is an inextensible 
loose fitting fibrous sac. Lining the pericardium is the serous 
pericardium which consists of two layers, the parietal layer which 
lines the inside of the fibrous pericardium and the visceral layer 
which is the outer surface of the heart. A small space containing a 
few drops of pericardial fluid lies between these two layers. This 
allows the heart to beat in the thorax with the minimum of friction.
The pericardium functions by limiting the maximum size of the 
chambers of the heart, thus preventing stretching of the cardiac 
fibres due to overfilling of the atria. The pericardium is attached 
to the diaphragm and when the heart beats it behaves as if the apex 
was relatively fixed. Thus, when the ventricles contract, instead of 
the apex moving upwards towards the base, the base and particularly 
the A-V ring descends towards the apex. This has the effect of 
increasing the size of the atria at the same time as blood is ejected 
from the ventricles.
4
Figure 1: The heart.
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( b )  STRUCTURE:
The wall of the heart consists of three layers of tissue: (i)
myocardium, (ii) visceral and (iii) endocardium. The myocardium is 
the main tissue. The visceral layer covers the myocardium and lining 
the inside of the myocardium is the endocardium. On the inside 
surface the myocardium is raised into ridge-like projections called 
papillary muscles. The heart muscle consists of cells known as fibres 
which are cylindrical in shape with central nuclei and faint 
striations. These muscular fibres are arranged in a complex manner, 
but in such a way that when they contract they tend to squeeze the 
blood in a forward direction into the next opening through which the 
blood has to pass. At the same time, some of the fibres of the two 
atria are continuous with each other and some of the right and left 
ventricle fibres are also continuous so that the two atria contract 
simultaneously and the two ventricles contract together.
(c) CHAMBERS:
The heart contains four chambers, two upper and two lower called 
atria and ventricles, respectively. The atria have relatively thin 
walls as they have to pump blood into the ventricles only. The wall 
of the right ventricle is thicker than that of the atria because it 
has to pump blood to the lungs. The wall of the left ventricle is 
thicker than that of the right ventricle because it pumps blood to 
the systemic circulation.
The muscle of the atria is entirely separate from the muscle of the 
ventricle except at one point. This point of communication is
artery thrombosis, and if the patient survives, the part of the 
myocardium supplied by the affected branch will become permanently 
deprived of its blood supply and the muscle will be replaced by a 
fibrous tissue scar. If this is extensive it will weaken the pumping 
power of the heart.
(f) THE CONDUCTION SYSTEM:
Certain tissues in the heart are concerned with the initiation and 
propagation of the heart beat. They include the S-A node, the A-V 
node, the A-V bundle and Purkinje fibres.
(i) S-A Node:
This is a small mass of modified cardiac muscle situated at the 
junction of the superior vena cava and the right atrium. These 
fibres normally initiate the heart beat, for this reason the S-A node 
is called the pacemaker. Nerve cells and fibres from the right vagus 
nerves and sympathetic nerves are also present.
(ii) A-V Node:
This is a specialised mass of cardiac muscle situated in the septum 
between the two atria. Atrial muscle fibres unite with the fibres in 
the A-V node. This node is identical in structure with the S-A node. 
The A-V node is supplied by the left vagus nerve and sympathetic 
nerve.
(iii) The Bundle of His and Purkinje Fibres:
These modified cardiac muscle fibres originate in the A-V node, pass 
down the interventricular septum and terminate in the walls of the
ventricles. The Bundle of His contains sympathetic and vagus nerve 
fibres and many blood vessels.
(g) THE NERVE SUPPLY:
Sympathetic fibres and parasympathetic fibres unite to form the 
cardiac plexus. Muscle fibres enter the heart from the cardiac 
plexus along with the coronary arteries. The sympathetic fibres 
which strengthen and accelerate the heart while those from the vagus 
slow the heart beat.
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1.2 PHYSIOLOGY:
HEART BEAT:
The heart beat originating as a contraction wave at the S-A node, 
spreads rapidly through the artrial muscle causing both atria to 
contract simulataneously. The blood in the atria is forced through 
the atrio-ventricular valves into the ventricles.
Rings of cardiac muscle around the entry of the superior and inferior 
vena cava and the pulmonary veins close off the veins with a 
sphincter-like action so that blood does not flow back into the veins 
when the atria contract.
The spread of the contraction wave through the cardiac muscle ceases 
at the fibrous septum between the atria and the ventricles which 
contains the four heart valves.
The only pathway through this non-conducting septum is from the A-V 
node down the atrio-ventricular bundle (Bundle of His). The 
contraction wave enters the ventricles near the apex and spreads 
upwards towards the base. The blood in the ventricles is forced 
upwards through the base of the heart and out through the aortic and 
pulmonary values. Figure 2.
1 0
Figure 2: Spread of the cardiac Impulse from the pacemaker
through A-V node and down the Bundle of His. A-B Is the septum
between the atria and ventricles. C-D Is the spetum between the 
chamber.
Sino-atrial 
Node Atrioventricular Node
Atrioventricular 
Bundle (Bundle of His)'
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1.3 PATHOLOGY:
No single simple classification of heart disease is possible. For 
this study the causes of heart disease may be divided into two 
categories:
(i) Mechanical e.g. valve defect or hypertension
(ii) Nervous/Electrical e.g. ectopic nodes
The symptoms of heart disease are many including chest pain, loss of 
breath, fainting etc. The same symptoms may arise from either a 
mechanical or nervous/electrical cause, Table 1.
1 2
Table 1: Shows some heart disorders and their causes.
DISORDER CAUSES
Congestive heart disease 
Rheumatic heart disease 
Mitral stenosis 
Ischaemia
High blood pressure 
Atrial septal defect 
Electrolyte imbalance 
Increase or decrease K+ 
Increase or decrease Ca2+
Ischaemia
Infarction
Electrolyte imbalance 
Pulmonary embolism 
Electrocution
13
Atrial Fibrillation 
Atrial Flutter
Ventricular Fibrillation
(a) Acute Myocardial Infarction:
This is the damaging or death of an area of heart muscle resulting 
from a reduction or blockage in the blood supply to that area. This 
is frequently caused by a thrombus in the coronary arteries.
(b) Congestive Heart Disease:
This often occurs as a result of structural defects in the 
myocardium. This may be caused by blockage of an arteriole supplying 
a small area of the right atrium. Consequently, the remaining heart 
muscle in the right antrium is overworked and loses its efficiency 
causing insufficient cardiac output to maintain adequate circulation. 
A backing up of blood in the veins leading to the heart often 
accompanied by accumulation of fluid in various parts of the body 
results.
(c) Atrial Arrhythmias:
These arise from loss of control of the sinus node over atrial 
contraction which becomes autonomous. The condition may or may not 
involve partial ventricular involvement.
(d) Ventricular Arrhythmias:
These are extremely serious as they are accompanied by total loss of 
cardiac output.
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(e) Atrial Flutter:
This condition has a regular pulse at 125-160/min with 
atrio-ventricular block.
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1.4 HISTORY OF DIGOXIN:
The control of abnormal cardiac rates or rhythms (arrhythmia) by 
medication dates back to the 18th century. William Withering [5] an 
English doctor introduced digitalis, an extract of the foxglove 
plant, to treat cardiac patients. He first became involved with the 
foxglove in 1775 when he was consulted about a family recipe for the 
treatment of dropsy (oedema) kept a secret by an old woman in 
Shropshire. The medicine consisted of twenty or more herbs and he 
recognised that the foxglove was the active substance present. He 
standarised the dose by using leaves from the plant only when it was 
in full bloom and administered it as a powder or infusion.
Withering's use of digitalis from 1775 to 1784 provided him with a 
complete description of its toxic effects. "Sickness, vomiting, 
giddiness, purging, confused vision, objects appearing green and 
yellow, increased secretion of urine with frequent motions to part 
with it and sometimes inability to retain it, slow pulse even as low 
as 35 in a minute, cold sweats, convulsions and death". Later as he 
became more familiar with the drug he modified its use "let it 
(digitalis) be continued until it either acts on the kidneys, the 
stomach or the bowels, let it be stopped at the first appearance of 
any of these effects".
Withering was impressed with its diuretic effect but he also noticed 
its effect on the heart.
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Today digitalis is prescribed as digoxin which was first isolated 
from the white foxglove (digitalis lanata) in 1930 [6] and was
accepted as a new drug in Martindale's Pharmacopoica of 1932. 
Another cardiac glycoside, digitoxin, was found in the purple 
foxglove (digitalis purpurea).
Subsequent to Withering's introduction of the drug a number of people 
misused the drug for nearly a century and its therapeutic value was 
doubted. It was used for many disorders often in toxic doses. In 
the early twentieth century its value in the treatment of atrial 
fibrillation was rediscovered. Since its extraction in the 1930s, 
digoxin is the most widely used form of cardiac glycoside in the 
British Isles [7]. However, in several European countries, a variety 
of other related glycosides, including digitoxin, lanatoside C and 
peruvoside, and semi-synthetic glycosides, such as ^-methyldigoxin 
are used. The greater popularity of digoxin over digitoxin is due to 
the fact that its therapeutic effect disappears in two days to one 
week following withdrawal of the drug, while the effect of digitoxin 
may persist for up to three or four weeks. This difference in 
metabolic behaviour is of great importance in the case of the toxic 
patient with serum digoxin greater than 2 nmol/1. Another reason for 
its popularity is due to the accumulation of large amounts of 
knowledge on its pharmacokinetics starting in the 1960s [8] and being 
pursued right up to the present time.
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1.5 CHEMISTRY:
Dlgoxin in a white crystalline powder with a melting point of 240°C. 
It is not very soluble in chloroform, ethyl acetate, acetone or water 
but is soluble in 80% alcohol solution when diluted 1 part to 122. 
It is soluble in pyridine when diluted 1 part in 4.
Figure 3 shows the chemical structure of digoxin and the related 
glycoside digitoxin. These compounds are composed of an aglycone, 
digoxigenin attached to three glycoside (digitoxose) moieties. The 
digoxigenin consists of a steroid moiety with an a-/9-unsaturated 
lactone ring coupled at C 17 of the steroid. The sugars are attached 
via the C3 hydroxyl groups. The type of sugar molecules present 
determine water and lipid solubility. The aglycone component imparts 
pharmacological activity to the drug. They are chemically related to 
bile salts, sterols, sex and adrenocortical hormones. The number and 
position of the OH groups on the digoxin molecule determines the 
protein binding capacity, its distribution and its excretion rate in 
the body. Saturation of the lactone ring results in major or total 
loss of drug action.
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Figure 3:
digoxin, p  -  O H  
digitoxin. R "  H i
Chemical Structure of Digoxin and Digitoxin.
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1.6 MECHANISM OF ACTION OF DIGOXIN:
Digoxin is used in the treatment of congestive heart failure, in the 
control of atrial fibrillation and flutter, and of supraventricular 
tachycardia [9], By far the most important of these uses is in
congestive heart failure.
Digoxin exerts its beneficial effect on the failing heart by 
increasing the force of systolic contraction (i.e. digoxin has a
positive inotropic effect) [10]. This occurs due to a specific 
interaction of the drug with the plasma membrane-bound ion transport 
system known as the Na+/K+ ATP-ase. This enzyme is responsible for 
the maintenance of the sodium and potassium concentration gradients 
across the plasma membrane of cardiac fibres [11] . These ion 
gradients are essential to the mechanism by which electrical impulses 
are generated and conducted through the heart. By pumping sodium 
ions to the outside of the cell and potassium to the inside, the 
transport ATP-ase causes intracellular ion concentrations of 
approximately 150 mmol/1 for K+ and 10 'mmol/1 for Na+ in contrast to 
extracellular concentrations of approximately 5 mmol/1 for K+ and 140 
mmol/1 for Na+ . Although this process is electrogenic it results in 
the nett removal of positive charges from the cell (3 Na+ are
transported to the outside for each 2 K+ions which enter the cell), 
the potential difference across the neuronal plasma membrane under 
resting conditions (the resting potential) is mainly due to the 
passive diffusion of potassium ions out of the cell along their
concentration gradient, the cell membrane being far more permeable to 
K+ than to Na+ under resting conditions.
20
The magnitude of the resting membrane potential in most cardiac 
muscle fibres is approximately -90 millivolts inside relative to 
outside, although the fibres of the S-A node have a resting potential 
of only -55 to -60 millivolts. This feature of the S-A fibres makes 
them more susceptible to self-excitation, a property which is related 
to their role in controlling the rate of beat of the entire heart.
Cardiac fibres are electrically excitable, that is they can convert a 
small depolarisation (decrease in membrane potential) into a 
fulminant but rapidly self-terminating reversal of the membrane 
potential which is known as an action potential. In order that an 
action potential is generated, it is necessary that the small 
depolarisation should achieve a certain minimum or threshold voltage 
below which no action potential is elicited and at or above which the 
events leading to the evocation of an action potential occur.
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Figure 4 shows a number of ion transport systems in the membranes of
the myocardial cell. Important factors in the mechanism of action of
digoxin and other cardiac glycosides are:
(1) The Na+ and K+ -ATP-ase or sodium pump. This contains the 
binding site for cardiac glycosides, which inhibit its ion 
transport activity resulting in an increase in the intracellular 
sodium concentration which the pump normally works to reduce 
after an action potential has passed. This increased 
intracellular sodium concentration seems to activate
(2) the reversible sodium calcium exchanger, which exchanges 
intracellular sodium ions for the uptake of calcium ions into 
the cell in a ratio of 3 Na+/1 Ca2+. Thus the inhibition of the 
sodium pump by digoxin results in an increase in intracellular 
sodium. The sodium then exchanges with extracellular calcium 
via the sodium calcium exchanger stimulating cardiac 
contraction. Also shown in Figure 4 are
(3) the K channel through which K+ ions leak out of the cell 
resulting in the resting membrane potential
(4) the voltage sensitive sodium channel whose opening in response 
to an impulse beginning in the S-A node results in 
depolarisation of the membrane due to an influx of sodium ions. 
This depolarisation leads to the opening of
(5) the slow calcium channel through which calcium normally enters 
the cell on stimulation. The influx of calcium ions causes the 
release of further calcium ions from the sarcoplasmic reticulum 
through its release channel
22
(6) the muscle cell is relaxed after stimulation by the removal of 
calcium into the sarcoplasmic reticulum or out of the cell by 
the ATP-dependent calcium pumps (7) and (8) respectively.
23
of the myocardial cell.
Figure 4: Some of the Ion transport systems In the membranes
Sarcoplasmic
Reticulum
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If the threshold depolarisation is exceeded specific voltage- 
sensitive membrane proteins become open channels selectively 
permeable to sodium ions. Sodium enters the cell down its 
electrochemical gradient through these channels until the membrane 
potential is reversed. The voltage-sensitive sodium channels then 
close and assume an inactive conformation which cannot respond to 
another depolarisation for a length of time which is known as a 
refractory period. After this time, during which the membrane is 
resistent to stimulation, the channels resume their original closed 
but voltage-sensitive conformation. Sodium ions that enter the cell 
through the voltage-sensitive channels, travel to neighbouring 
portions of the membrane, depolarising them sufficiently to exceed 
the threshold voltage and initiate an action potential in them by 
causing a rapid influx of sodium through the voltage-sensitive 
channels. In this manner electrical signals are conducted along the
fibre.
Coupling of electrical excitation of the fibre to contraction is 
mediated by an increase in the intracellular concentration of calcium 
ions (Figure 4) which, by binding to the protein troponin removes the 
inhibition of interaction of the contractile filaments of actin and 
myosin. In the relaxed muscle this inhibition is caused by troponin 
and another protein, tropomyosin, which is thought to cover the 
active sites on the actin filaments.
In the case of cardiac muscle fibres the source of this calcium is 
mainly extracellular but there may also be a contribution from the 
intracellular stores of the sarcoplasmic reticulum. This contrasts
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with the situation in skeletal muscle which utilises intracellular 
calcium stores to release calcium into the sarcoplasmic fluid. 
Cardiac muscle, unlike skeletal muscle, may utilise the sodium ions 
gained during excitation to contribute to the increase in 
intracellular Ca2+ . It does this by means of the Na+/Ca2+ exchange 
mechanism of the plasma membrane, exchanging internal Na+ ions for 
extracellular calcium. This system could operate, in addition to the 
voltage- dependent calcium channels of the plasma membrane, as a 
mechanism whereby the intracellular calcium concentration is 
increased.
Although the changes in sodium and potassium concentration in the 
cell caused by each impulse are minute and many action potentials can 
be conducted before the loss of transmembrane ion gradients affect 
the excitability of the cell, it becomes necessary with time to 
re-establish these transmembrane sodium and potassium concentration 
gradients. This is the function of the Na+/K+ ATP-ase and it is this 
mechanism which is inhibited by digoxin.
A possible explanation of the positive inotropic effect of digoxin
+ 2+based on its inhibition of the Na /Ca ATP-ase, involves the
+ 2+activation of the reversable plasma membrane Na /Ca exchange system 
by the increased intracellular sodium concentration, with the 
resultant increase of intracellular calcium causing increased 
contractile activity.
Another interesting mechanism by which digitalis can modulate 
myocardial contractile force, at least under experimental conditions
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in vitro is stimulation of the release and blockage of reuptake of 
noradrenaline from adrenergin (sympathetic) nerve terminals in intact 
myocardium.
Since the sodium-potassium ATP-ase is electrogenic and transports 3 
Na+ ions out of the cell for every 2 K+ ions transported into the 
cell it tends to increase the membrane potential of excitable cells. 
It also prolongs the period of hyperpolarisation which follows each 
action potential and prevents re-excitation and the generation of 
another action potential. Thus, digoxin would be expected to shorten 
the time between^ action potentials, i.e. decrease the refractory 
period of excitable cells. What has been observed is that digoxin 
does decrease the refractory period in heart muscle cells, but in 
contrast to this effect, digoxin (and other cardiac glycosides) 
increase the refractory period and slow the conduction of action 
potentials in specialised cardiac conducting tissue such as the S-A 
node (in which the normal rhythmic self-excitatory impulse is 
generated) and the A-V node (in which the impulse from the atria is 
delayed before passing into the ventricles). These effects on the 
S-A and A-V nodes are mediated by the potentiating effect of digoxin 
on the vagal nerves. This is probably caused by the inhibition of 
monovalent cation transport in the nerves but detailed mechanisms are 
not well understood. Increased vagal activity causes the release of 
the neurotransmitter acetylcholine which has two major effects on the 
heart. First it decreases the rate of rhythm of the S-A node and 
second, it decreases the excitability of the A-V junctional fibres 
between the atrial musculature and the A-V node, thereby, showing 
transmission of the cardiac impulse into the ventricles.
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The effects of acetylcholine are mediated by an increase in the 
permeability of the fibre membranes to potassium which allows rapid 
leakage of potassium to the exterior, resulting in hyperpolarisation 
which as mentioned above makes excitable cells much less excitable. 
The vagus nerves which supply the heart are distributed mainly to the 
S-A and A-V nodes, to a lesser extent to the muscle of the two atria 
and even less to the ventricular muscle. This may explain the 
contrasting effects of digoxin on the refractory period of working 
heart muscle and that of the specialised conducting fibres.
These actions of digitalis are used to advantage in the management of 
superventricular tachyarrhythmias, including atrial fibrillation or 
atrial flutter, both of which involve abnormal rapid contractions of 
the atrial muscle. By prolonging the refractory period of the A-V 
node, causing many of the atrial impulses which enter the node to be 
extinguished within it, digoxin reduces the ventricular rate. In the 
case of atrial flutter, a more serious condition than fibrillation, 
the abnormal contractions in the atrium are more co-ordinate, and by 
its non-uniform effects on the refractory period of atrial muscle, 
digoxin can convert atrial flutter to atrial fibrillation.
Digoxin has a slowing effect on the heart rate by its action on the 
S-A node, but it should be noted that digoxin's slowing action on the 
failing heart may be secondary to its improvement in circulation i.e. 
digoxin causes a reduction in compensatory tachycardia.
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At toxic levels, digoxin can also trigger arrythmias by generating 
ectopic beats or by blocking A-V transmission resulting in dropped 
beats. Other arrythmias may result from increased vagal activity.
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1.7 PHARMACOKINETICS:
(a) ABSORPTION:
The degree to which digoxin is absorbed and made available to the 
systemic circulation varies markedly from one preparation to the next 
and many reports of toxic digoxin concentrations can be due to a 
patient changing from one formulation to the next [12-14]. The
narked difference In digoxin concentrations Is due to the different
>
dissolution rates of the tablet given [15].
Figure 5: The time curve of the serum concentration of the three
different preparations of digoxin given orally to one 
patient.
Studies show that a mean of 67% of digoxin administered as an oral 
tablet Is absorbed from the gastro-intestinal tract in 60-90 minutes 
after administration and the maximum therapeutic effect is apparent 
in 3-6 hours [16]. Absorption of digoxin after oral administration 
of an elixir accounts for only 801 of the administered dose.
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Absorption from intramuscular injection sites is variable and 
incomplete. Intramuscular injection should be avoided as this can 
cause pain and tissue necrosis [16]. The absorption of encapsulated 
elixir is 90-100%.
After oral administration of digoxin the blood concentration rises, 
the rate at which it increases depends on the absorption. During the 
absorption phase a time is reached when the rate of digoxin output 
equals digoxin input. At this point a maximum concentration of 
digoxin is reached in the serum. Subsequently, the concentration 
falls as a result of the output of digoxin being greater than the 
input. The area under curve A or B is a measure of the degree of 
absorption (i.e. the bioavailability).
A reduction in digoxin absorption may also be caused by a number of 
factors including drug - drug interactions and malabsorption 
syndromes [16] (Table 2). Malabsorption of digoxin may be caused by 
motility- stimulating drugs such as metoclopramide. Increased 
absorption of digoxin may occur as a result of anti-cholinergics 
which decrase intestinal motility [17]. In approximately 10% of 
patients antibiotics may increase its absorption by preventing its 
hydrolysis by intestinal bacteria. Although these and other diseases 
account for some altered digoxin absorption it has been found that 
some normal individuals have absorbed as little as 48% of orally 
administered digoxin tablets [18].
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Table 2 : Factors influencing absorption of digoxin tablets.
FACTOR EFFECT
Reduced gastro­
intestinal motility
Increased absorption
Fast dissolution rate Increased absorption
Increased gastro­
intestinal motility Decreased absorption
Sprue Decreased absorption
Hyperthyroidism Decreased absorption
High fibre diet Decreased absorption
Slow dissolution rate Decreased absorption
Prior food intake No effect
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(B) DISTRIBUTION:
After absorption of the drug into the systemic circulation it is 
distributed to the various body fluids and tissues. The distribution 
of digoxin after intravenous injection or infusion of the drug can be 
described by a model which consists of two pharmacokinetically 
distinct compartments [19]. The first rapid decrease in
concentration is due to the dilution effect of the circulation and 
requires a few minutes to complete with a half-life of 2 minutes. 
The second stage is the distribution phase (a) during which digoxin 
reaches an equilibrium between the central and peripheral compartment 
[20] . The serum digoxin concentration reflects the cardiac activity 
during this stage. The central compartment can be assumed to 
represent plasma and highly perfused organs such as liver and 
kidneys. The peripheral compartment represents the deeper tissues, 
especially skeletal muscle and myocardium. The largest concentration 
of digoxin is stored in skeletal muscle even though digoxin 
concentration is less in skeletal muscle than in myocardium during 
maintenance therapy. The ratio of the plasma and heart concentration 
of digoxin lies between 1:30 and 1:200 [21-22].
Digoxin is widely distributed in the tissues as shown by the large 
apparent volume of distribution of about 61/kg. The extent to which 
the drug is distributed in the body at equilibrium (i.e. when output 
is equal to input) is called the apparent volume of distribution, and 
thus is defined as the volume of body water which would be required 
to contain the total body digoxin concentration at the concentration 
present in plasma. The apparent volume of distribution varies from
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about 3-10 1/kg body weight [23]. This shows the extent of digoxin 
binding to tissues.
In renal failure the apparent volume of distribution of digoxin can 
be reduced [24], with a 33% to 50% reduction in patients with severe 
renal impairment. It is also altered in thyroid disease, being 
decreased in hyperthyroidism and increased in hypothyroidism. The 
time required to complete the distribution phase after oral digoxin 
tablet administration is between 8-12 hours [25]. When serum digoxin 
concentrations are estimated for evaluating cardiac response the 
blood sample should be drawn at least eight hours and, and 
preferably, eighteen hours after drug administration. Samples taken 
prior to this will show falsely elevated serum concentrations. Once 
the distribution phase is complete drug elimination from the body 
begins to occur.
(c) METABOLISM:
Until recently it was assumed that digoxin was not significantly 
metabolised [26]. Today it is accepted that extensive metabolism can 
occur. The metabolism of digoxin may include saturation of the 
lactone ring to form a low cardioactive compound called 
dehydrodigoxin. It has been suggested that bacteria present in the 
bowel are responsible for this reaction and it may be reduced in 
people on antibiotics. Consequently, the route of administration 
will govern the extent of conversion to these compounds. The 
metabolism can also involve the stepwise removal of three sugar 
moieties to form digoxigenin followed by epimerization of the 3-
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/3-hydroxyl to the 3-a position and conjugation to give 3-epi- 
glucuronide and 3-epi-sulphate [27-28]. These are shown in Figure 6.
Metabolism of digoxin to either the dihydrometabolites or the 
digoxigenin conjugates renders digoxin cardioinactive, however, both 
the mono and di-sugars are cardioactive. There is wide
interindividual variations in the metabolism of digoxin with some 
individuals demonstrating a large biotransformation of the drug [29]. 
A study involving both an RIA and combined RIA chromotography 
technique used serum from nineteen patients on digoxin. The results 
show that metabolites accounted for between 1-99% of the 
radioactivity measured. Thus, the method chosen for digoxin 
estimation must be specific.
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Figure 6 : Digoxin Metabolism
DIGOXIN ------------------------1 —  DIHYDRODIGOXIN 1■4-
DIGOXIGENIN
+
DIHYDRODIGOXIGENIN
Bis-digitoxiside (2 sugars) 1
DIGOXIGENIN Conjugation
Mono-digitoxoside (1 sugar)i products
DIGOXIGENIN (no sugar) ------ — ► Epi-dlgoxigenin
— ► Conjugation
products
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Figure 7: The Nephron.
Distal Convoluted Tubule
Loop of Benle
Proximal Convoluted 
Tubule.
Malphigian Corpuscle
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(d) SECRETION:
Digoxin is excreted by the kidneys both as the unchanged digoxin and 
its metabolites. Digoxin which circulates free (unbound) is filtered 
by the renal glomerulus (Figure 7).
Some of the digoxin in the glomerular filtrate is passively 
reabsorbed by the proximal tubule and there is also some secretion of 
digoxin by the cells in the distal tubules into the glomerular 
filtrate [30-31], In some cases the amount of digoxin absorbed 
equals that secreted so that in these individuals the renal clearance 
is equal to the rate of glomerular filtration of the fraction of 
digoxin which is unbound. Patients with renal failure have decreased 
renal digoxin clearance and in many cases the renal clearance of 
digoxin can be calculated from creatinine clearance [32]. However, 
in some patients with congestive cardiac failure and prerenal 
azotemia, renal excretion of digoxin is reduced due to an increase in 
proximal tubular reabsorption from the glomeruler filtrate [33].
Drugs such as quinidine and spironolactone inhibit renal clearance 
of digoxin. Quinidine [34] inhibits distral tubular secretion of 
digoxin, resulting in decreased renal clearance. It also decreases 
the apparent volume of distribution of the drug. This causes an 
increase in plasma digoxin leading to an increased incidence of 
digoxin toxicity. Spironolactone also inhibits renal tubular 
secretion of digoxin by approximately 25%.
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Complete elimination of digoxin from the plasma involves both renal 
excretion and hepatic metabolism. Some years ago it was believed 
that digoxin was eliminated primarily by the kidneys (60-80%). 
However, recent investigations have demonstrated that 
dihydrometabolites can account for a major part of digoxin excretion. 
It has been shown that metabolism accounts for 75% of total 
elimination [24] in patients with severe renal impairment.
(e) HALF-LIFE:
The half-life of digoxin in patients with normal renal function 
reportedly varies between 26 and 45 hours [35] and is prolonged to 92 
hours in anuria. This means that in a patient with renal failure it 
will take longer to achieve a steady state during maintenance therapy 
and longer for excretion of digoxin than in patients with normal 
renal function. Pharmacokinetic variables related to digoxin are 
summarised in Table 3.
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Table 3: Some pharmacokinetic variables related to digoxin.
Oral Dose Absorbed % 48-85
Protein Bound % 20-25
Half-Life Adults 26-45 Hours
Children 11-50 Hours
Time To Reach Peak Plasma Concentration 1.5-5 Hours
Time To Reach Steady State (Adults) 7-11 Days
Time To Reach Steady State (Children) 2-10 Days
Apparent Volume of Distribution 3-10 Kg/L
Effective Blood Concentration 1-2.5 nmol/L
Toxic Blood Concentration > 2 . 5  nmol/L
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1.8 INDICATIONS FOR MEASURING PLASMA DIGOXIN:
Digoxin may produce either therapeutic, toxic or lethal effects 
according to the dose administered. The therapeutic effect is seen 
as an improvement in the efficiency of myocardial contraction without 
requiring a simulaneous increase in oxygen. The toxic and lethal 
effects of digoxin show themselves as ventricular arrhythmias which 
are increasingly severe and may possibly be fatal with increasing 
dosage.
Proper management of digoxin dosage and avoidance of toxic conditions 
is a complex and difficult task. The response of an individual 
patient may change over a period of maintenance dosage. Changes in 
response to digoxin therapy arise from two causes:
(a) CHANGES IN PATIENTS' SENSITIVITY:
In thyroid disease plasma digoxin concentrations are altered by two 
different mechanisms - by a change in the apparent volume of 
distribution and by a change in renal elimination. Thus, in 
hyperthyroidism the apparent volume of distribution is increased and 
renal clearance is increased. These effects result in lower plasma 
digoxin concentrations both after a loading dose and at steady state. 
In some patients with renal failure the apparent volume of 
distribution is reduced and the extent of reduction seems to be 
related to the degree of renal impairment. An increased sensitivity 
of digoxin can be noted in states of hypokalaemia, hypomagnesaemia 
and hypercalcemia which make establishment of the true therapeutic
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concentration of digoxin difficult. Digoxin concentration may be 
affected due to interference by co- administration of other drugs 
such as quinidine, aspirin, quinine and acetominophen. Serum levels 
of digoxin have been shown to be increased significantly by the first 
three of these drugs. Serum creatinine levels were not affected by 
administration of these drugs. It appears likely that the increases 
are due to a reduction in digoxin clearance.
(b) MODIFIED ABSORPTION AND EXCRETION OF THE DRUG:
This may result in sudden changes in circulatory levels of digoxin 
during a maintenance regimen. In patients undergoing sudden 
alterations in renal functions over or underdosing may occur. In 
this situation the serum digoxin along with clinical correlation with 
the desired therapeutic effect is desirable. Modified absorption may 
also be due to variable bioavailability of digoxin from different 
pharmaceutical drug preparations. Gastrointestinal problems may 
affect absorption of orally administered digoxin. Rapid
gastrointestinal tract transit may result in a low serum digoxin 
concentration whereas delayed gastric emptying may result in better 
absorption of the drug due to more thorough dissolution.
It has been estimated that between 11-36% of patients assumed to be 
on appropriate maintenance doeses of digoxin were found to be 
underdigitalized. One reason for this may be due to lack of
compliance. The serum digoxin concentration will help to establish 
whether the patient is failing to take his medication properly.
Patient compliance is a major determinant of serum digoxin
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concentration [36]. If a patient who claims to be taking his 
medication shows a low serum concentration of the drug the doctor is 
alerted to the need for further studies or perhaps further discussion 
about compliance with the patient.
The ratio of toxic dose to therapeutic dose for a drug is known as 
the therapeutic index. For digoxin this index is small
(approximately 2 to 3). There also exists the possibility that a 
dose which is therapeutic for one patient may be toxic for another. 
Unfortunately the symptoms and signs of digoxin toxicity such as 
headache, nausea and bradycardia are not specific. A reduction in 
symptoms and signs when digoxin is stopped helps to establish the 
diagnosis of digoxin intoxication.
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Chapter 2
DIGOXIN CONCENTRATION MONITORING
2.1 INTRODUCTION:
There are a large number of methods available for the measurement of 
digoxin in plasma. Over the last number of decades digoxin 
methodologies have changed with advances in instrument technology. 
Some of these methods have also been modified for salivary digoxin 
measurement.
Prior to 1949 the effect of digitalis activity on intact animals such 
as cats and guinea pigs was used to determine the minimum lethal dose 
required to induce vomiting. These methods were insensitive and were 
used only for assaying tablet content of the drug [37].
Since 1949, many different methods have been described. Although 
there is a wide choice most assays can be assigned to one of three 
groups:
2.2 Chromatographic techniques which include T.L.C., G.L.C. and 
H.P.L.C.
2.3 Bioassays
2.4 Immunoassays.
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2.2. CHROMATOGRAPHIC TECHNIQUES:
2.2.1 Thin Layer Chromatography:
T.L.C. involves a thin layer of silica gel uniformly spread onto 
glass plates, plastic sheets or other suitable inert materials [38]. 
The sample to be analysed is concentrated in a suitable solvent and 
added as a concise spot or streak near an edge of the plate which is 
then placed in a closed glass container with the lower edge of the 
plate in contact with the mobile phase. Although the major factor in 
determining the chromatographic properties of digoxin is its 
molecular structure, important modifications are brought about by 
changes in the composition of the solvent system. This results in 
changing the retention values of the components in the mixture.
The next stage in T.L.C. is to detect the position to which the spots 
have run. This may be achieved by using standards, dyes, or Rf 
values. The ratio of the distance that a specimen spot has moved 
from the point of application to the solvent front is called the Rf 
value. One major difficulty is the quantitative assessment of the 
spots. Quantitation of components separated from the mixture can be 
carried out on the plate or after the spots containing the components 
have been scraped from the plates and eluted from the absorbent. 
Quantitation in situ can be performed using a densitometer.
Since T.L.C. on silica gel was first used to separate cardioactive 
glycosides [39] numerous T.L.C. systems have been published. It was 
recognised that separation of complex mixtures of cardioactive 
glycosides could not be achieved by conventional T.L.C. [40] and
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Further improvements were introduced through the use of a continuous
development technique which involved a trough filled with absorbent 
material attached to the top edge of the T.L.C. plate to take up the 
mobile phase [41].
In 1972 [42] a method was described which separated digoxin,
digitoxin and their metabolites by paper chromatography and then by 
T.L.C. The spots were identified by their Rf values and then further 
characterised by G.L.C. equipped with an electron capture detector 
after making volatile derivatives. This has a sensitivity of 25 
picomoles/1 of digoxin in plasma.
T.L.C. is a qualitative test for digoxin. Quantitation from the 
T.L.C. plates is limited by the amount of digoxin which can be 
isolated, the degree of contamination with other components and the
loss of the component because of incomplete elution from the
absorbent. T.L.C. systems are simple and economical in that they 
require no expensive equipment outlay. However, the drawback to this 
method lies in the technical capability and experience needed to 
interpret the chromatograms produced as the plate is sprayed with 
various reagents. The results depend upon subjective interpretation 
and the metabolites of digoxin present in the sample may produce 
interference.
T.L.C. offers advantages in terms of cost over all other 
chromatographic processes. However, it will remain an unsuitable 
method for digoxin analysis until such time as the procedure is 
automated.
improved resolution was obtained by using two dimensional T.L.C.
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2.2.2 Gas Liquid Chromatography:
G.L.C. is a process in which a mixture of compounds in volatilized 
form is separated into its constituent components by using a mobile 
phase over a stationary phase [43], Therefore, the chromatography
has to be performed at high temperatures which are maintained by
placing the column in an oven. The mobile phase is an inert gas 
(hydrogen or helium) that carries the sample extract over a liquid 
stationary phase in the column. The stationary phase is packed into 
a column in which one end is connected to an inj ector where the 
sample and inert gas are introduced. The other end of the column is 
connected to the detector.
The chromatographic separation is achieved by diffusion, 
partitioning, or adsorption between the mobile gaseous and the 
stationary liquid phases. The retention time for digoxin is the time
it takes for the peak to emerge after injection. The retention time
of digoxin can be increased or decreased by adjusting the temperature 
of the oven or by using liquid phases of differing polarity.
Most G.L.C. systems for digoxin use an electron capture detector 
which responds proportionately to the concentration of digoxin in the 
sample. Mass ionization detectors are very sensitive but their cost 
and maintenance requirement prohibit their use in most clinical 
laboratories. Nitrogen phosphorous detectors are also very sensitive 
and can detect picomole levels of the drug.
As most digoxin levels are performed using serum or plasma an 
extraction procedure is necessary so as to separate the drug from the
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supporting matrix. This has the advantage of separating digoxin from 
its metabolites. The specificity of most chromatographic methods 
makes them suitable for digoxin estimation. However, because of the 
low concentration of digoxin in serum, sensitivity may still cause 
problems. In order to improve sensitivity large sample volumes or 
derivitization is required.
In 1971 a GLC method [42] was introduced in which the serum was 
extracted using methylene chloride. The extract was derivitized with 
heptafluorobutyric anhydride followed by T.L.C. which was then 
subjected to G.L.C. using an electron capture detector. Tritiated 
digoxin was used as an internal standard. The method required 5ml of 
plasma and up to five hours of analysis time and consequently, was 
not very suitable for routine laboratory work except for use in 
research. The sensitivity was 0.52 nmol/L with a CV of 11% on a 
specimen containing a digoxin concentration of 3.5 nmol/L. The 
advantages and disadvantages are summarised in Table 4.
In general G.L.C. with its present refinements has much to offer in 
therapeutic drug monitoring. It is however, not the method of choice 
for digoxin measurement.
Table 4: Some characteristics of the G.L.C. technique.
ADVANTAGES DISADVANTAGES
Good precision
Stat analyses 
Cheap reagents
Semi-automation 
Very specific 
Very sensitive
Extraction and chromato­
graphy required
Large sample size
Not suitable for paedaitric 
samples
Sequential analyses
Gas supplies required
High degree of expertise 
required
Equipment expensive
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2.2.3 High Performance Liquid Chromatography:
In H.P.L.C. [44] digoxin and its metabolites in a specimen are 
separated on the basis of the different molecular functional groups 
of each compound by selective interaction between the two phases. 
Reverse phase H.P.L.C. is the most widely used form of H.P.L.C. for 
digoxin estimation and it requires a non-polar stationary phase. The 
most popular reverse phase column packing is the octadecyl type in 
which a C hydrocarbon is covalently bonded to silica particles and 
packed into a narrow tubular steel or plastic column.
Separation depends upon the affinity of the compound with the two 
phases. Compounds with strong affinities to the stationary phase 
will emerge after those having affinity towards the mobile phase. 
The mobile phase consisting of a mixture of solvents feeds into a 
pumping system capable of delivering uniform pulse-free flow to the 
chromatographic column. The injector is installed between the pump 
and the column. This does not disturb the flow system. The other 
end of the column is connected to a short flow-through cuvette in a 
detector. The detector uses either uv light, fluorescence or 
chemical ionisation analysis. The signal is recorded on a strip 
chart recorder or an electronic integrator. Qualitative and 
quantitative analysis is performed by measuring the height or area of 
the peak recorded. Good sample preparation is very important in 
H.P.L.C. so as to avoid column plugging. In 1975 [45] a H.P.L.C. 
method for the separation of digoxin and its metabolites was 
described. This involved an isocratic system using mixtures of 
acetonitrile and water as mobile phase for the separation of digoxin, 
bis- and monodigitoxosides and digoxigenin. A gradient system was
also used. Separation of the compounds was accomplished in less than 
thirty minutes. The sensitivity of the method used in conjunction 
with a uv detector (220 nm) was 5.2-26 nmol/L thus this method was 
unsuitable for therapeutic drug monitoring in which the therapeutic 
range for serum digoxin is 1.3-2.6 nmol/L.
Since H.P.L.C. is performed at ambient temperature the composition of 
digoxin and its metabolites is not a problem. Thus each of the 
compounds can be collected separately as they elute from the column. 
Once the compounds have been separated they may then be subj ected to 
quantitation by other more sensitive methods.
In 1980 such a method involving H.P.L.C. and RIA was used to measure
3digoxin [46]. Digoxin was extracted using H digoxin as an internal 
standard. This method only required 1 ml of plasma and CVs of 6-10% 
were obtained in plasma samples containing 0.65 and 3.25 nmol/L of 
digoxin compared with a CV of 4% for RIA. In 1985 a method was 
described which involved small column extraction of serum, combined 
with H.P.L.C. and RIA of the eluted fractions [47]. Using digoxin 
standards of 1.3, 0.65 and 0.13 nmol/L analytical recoveries of 95%, 
93% and 84%, respectively, were achieved. The method gave CVs of 
4-6% for sera with values of 0.65-1.3 nmol/L. The limitations of the 
method was that dihydrodigoxin eluted simultaneously with digoxin. 
Finding a suitable internal standard for the method was also 
difficult. It was costly on account of the fact that ten one ml 
fractions of the H.P.L.C. were required to define the peak for 
digoxin and determine the concentrations in each fraction by RIA. 
None of the endogenous DLIFs or drugs showed a peak with the 
retention time of digoxin.
Pre-H.P.L.C. column derivitization of digoxin with chemicals to 
increase uv absorbance or for fluorescence detection has been useful 
in explanations of drug metabolism and excretion, but detection 
limits are still too high for the picomole amounts of digoxin that 
are present in reasonable volumes of serum [48-50]. Post H.P.L.C. 
column reaction with hydrochloric acid to produce a fluorescent 
species has permitted quantification in serum sample volumes of 3ml 
[51] and 0.5ml [52] but requires elaborate instrumentation. Some
H.P.L.C. methods are shown in Table 5. In cases in which patients 
have renal failure or liver dysfunction, in neonates or third
trimester pregnant women, digoxin immunoassays usually yield 
unreliable results. The use of chromatographic analysis in these 
cases, combined with an immunoassay method will give improved results 
[47].
In general H.P.L.C. procedures are labour intensive and time
consuming involving an extraction and chromatographic step. The 
large sample size requirement may not make it suitable for paediatric
analysis. In order to introduce such a method into a small
laboratory a great amount of time in training laboratory staff and 
expenditure in new equipment is required.
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Table 5: Evaluation results using different detection systems in
combination with H.P.L.C.
DETECTION
PRINCIPLES
PRECISION SENSITIVITY SEPARATION REF
RIA 0 - 10% 0.65 nmol/L Extraction 46
Fluorescence 4 - 6% 0.29 nmol/L Extraction and 
Derivitization
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Fluorescence 5 - 7% 0.29 nmol/L Extraction and 
Derivitization
52
RIA 4 - 6% 0.29 nmol/L Extraction 47
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2.3 B I O A S S A Y S :
A bioassay is normally used for measuring drug levels in which the 
drug itself may not be in pure form. As the drug may exist in impure 
form bioassays can be used to measure the actual response of the 
drug.
ERYTHROCYTIC Rb UPTAKE INHIBITION ASSAY:
This bioassay for digoxin measures the inhibition of red cell
rubidenium 86 uptake into the red cell [53]. The method has been
used both in research and as a routine method for digoxin, digitoxin
and cardioactive metabolite estimations. The assay depends on the
fact that digoxin inhibits Na+/K+ ATP-ase on the red cell membrane
86and consequently the transport of Rb into the red cells. The drug
is extracted from plasma using methylene chloride and the extract
incubated with human red cells. The 86Rb uptake is quantified using
a standard digoxin calibration curve. Some of the limitations of the
method are shown in Table 6. However, as the assay measures total
cardioactive glycosides (that is digoxin and its metabolites which
inhibit Na+/K+ -ATP-ase) more useful information is obtained than that
for immunoassays which use antibodies with different specificities
and varying degrees of cross- reactivity for digoxin, its metabolites
86and DLIFs. However, comparisons between Rb technique and RIA 
methods have shown good correlation. In one study of 100 patients 
good correlation between 72 patients was found [54] and a valid 
reason for discrepancy between 22 of the 28 remaining cases existed.
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assay.
86Table 6 : Limitations of the Erythrocyte Rb uptake Inhibition
(a) Extraction required
(b) Sample volume - 1 ml
(c) Measures dlgoxin and dlgltoxln
(d) Time consuming - up to seven hours
(e) Interference due to Na+/K+ - ATP-ase inhibitors
(f) Washed erythrocytes required
(g) Sensitivity 3.9 nmol/L
(h) Precision 6-10%
*
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In another study of 27 patients [55] there was a good correlation 
(n=0.83) between 23 of the cases with the remaining 4 showing wide 
discrepancy.
In 1972 a receptor assay was developed [56]. This method used
3displacement of H-ouabain from ATP-ase rich cardiac muscle 
homogenates from guinea pigs to estimate digoxin in a competitive 
protein binding assay. This technique assayed cardioactive
glycosides present in the serum. The method had the advantage of 
measuring digoxin and its metabolites relative to their 
cardioactivity. It did not distinguish between cardiac glycosides so 
it was important to know which digitalis preparation the patient was 
on. Otherwise a maintenance digitoxin level (13-39 nmol/L) might be 
interpreted as a toxic concentration for serum digoxin. Table 7 
shows some of the characteristics of the method.
Recently a study using ATP-ase receptors from dog kidney were used 
but it had limitations similar to the last method [57] . In a 
receptor technique recently developed ATP-ase receptors from human 
heart were used [58], This method gave very good precision and 
sensitivity of 7 nmol/L. This may be due to the greater 
concentration and affinity of ATP-ase receptors in cardiac muscle. 
The cardioinactive metabolites do not participate in the reaction and 
the cardioactive metabolites are detected relative to their 
cardioactivity.
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Table 7: Some characteristics of the receptor assay.
(a) Extraction and competitive protein binding assay
(b) Sample size 5ml
(c) Sensitivity 0.26 nmol/L
(d) Exact specificity not found
<e) Measures ouabain, digoxin and digitoxin
<f) Lability of enzyme a problem
(g) As convenient as immunoassay methods except for 
sample size and complicated extraction step
*
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A sample pretreatment step using sep-pak C cartridges is required18
to remove DLIF. However, the method has not been fully evaluated 
yet.
*
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2.4 IMMUNOASSAYS:
The first immunoassay for a drug was described for digitoxin in 1968 
[59]. Since then several types of immunoassays depending on the 
detection system used have been described.
In this review, the following types of immunoassays applicable to 
serum digoxin determination are discussed.
2.4.1 Radioimmunoassays
2.4.2 Enzymeimmunoassays
2.4.3 Fluorescenceimmunoassay
The various assays may be further classified on the basis of (1) 
which reactant is to be measured; (2) which reactant is labelled 
(antigen or antibody); (3) whether the reaction is competitive or
non-competitive; and (4) whether the assay is homogenous or 
heterogenous.
Homogenous assays do not require a separation step to distinguish 
bound from unbound digoxin. The property of the labelled molecule is 
regulated by the antibody - antigen reaction such that separation of 
free and bound label is not required. Heterogenous assays for 
digoxin require a separation step to separate bound labelled digoxin 
from free labelled digoxin.
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2.4.1 Radioimmunoassays:
The RIA method [60] for digoxin was developed in 1969 by building on 
the work of Barson and Yalow [61] who prepared digitoxin antibody. 
Digoxin is a small molecule and, therefore, rarely able to induce 
antibody formation by itself; for this reason, it was conjugated to 
bovine serum albumin [60]. The conjugate is formed by periodate 
oxidation of the vicinal hydroxyl groups of the enol sugar to form 
aldehyde groups which react with the amino groups of bovine serum 
albumin. Thus, the conjugate linkage is through the carbohydrate 
moiety of digoxin. The antibody induced by this conjugate is mainly 
directed against the steroid part of digoxin. Consequently, 
digoxigenin, bis- and monodigitoxide and digoxigenin all react with 
the antibody, whereas dihydrodigoxigenin and dihydrodigoxin, each 
with C 22 reduced, exhibit little or no cross-reactivity. Indeed for 
some antisera the carbohydrate deficient metabolites are more potent 
antigens than is digoxin itself, the additional carbohydrate units of 
digoxin in some way reducing the antibody binding capacity. The 
cross-reactivity of the metabolites of digoxin with the anti-digoxin 
antibodies in immunoassays is well known and for most commercial 
anti-digoxin sera the degree of cross-reactivity is stated. Cross­
reactivity occurs with other medications such as spironolactone, 
hormones such as progesterone, testosterone, dihydroxye- 
piandrosterone, and compounds with other steroidal configurations. 
Interferences, caused by peptides, fatty acids and DLIFs, (Chapter 
3), have been demonstrated.
Prior to immunization the conjugate was mixed with one of the many 
adjuvants such as Freund's or acrylamide gel and injected into a
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rabbit or goat. Injections were repeated until the animal produced a 
specific antibody against the digoxin moiety. The antibody was then
_ 3labelled with an isotope. In the original RIA method H, which is a 
/J-emitter, was used. Its use was discontinued due to interference 
caused by haemolysis, hyperbilirubinemia, hypertriglyceridemia and 
autoluminescence in the serum of uraemic patients. The interference 
was due to light photons produced as a result of the effect of /?- 
emissions on the scintillation solvents being either totally or
125partially absorbed. Instead I labelled digoxin, which emits gamma 
rays and is unaffected by colour and chemical quenching, was used.
In general, RIA systems are heterogenous. When applied to digoxin 
these assays may be (a) competitive; (b) non-competitive (sequential 
method); (c) solid phase or fluid phase; or (d) antigen labelled.
(a) Competitive RIA:
125This is a radioimmunoassay where I - labelled digoxin competes for 
a fixed time with digoxin in the patient sample for antibody sites. 
The concentration of the antibody labelled digoxin is inversely 
proportional to the serum digoxin concentration (Figure 8).
(b) Sequential Method:
Unlabelled antigen is first mixed with excess antibody until 
equilibrium is reached. The next step involves the addition of 
labelled antigen and after a suitable incubation time the bound and 
free counts are determined after separation. This results in a 
higher fraction of serum digoxin binding by the antibody than in a
competitive assay where the ultimate sensitivity limit is dictated by 
the affinity constant of the antibody.
*Ab + Ag + Ag
J LXAg - Ab + Ag - Ab* + Ab
Phase Separation
* *Ag -Ab Ag
----► +
Ag-Ab Ag
Bound Fraction Free Fraction
Figure 8: Principle of RIA. A limited number of antibody
binding sites (Ab) a constant amount of 
radiolabelled antigen (Ag ) and different 
amounts of antigen (Ag) are incubated and a 
suitable technique is used to separate the free 
and bound antibody fractions at equilibrium.
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(c) Phase Separation Method:
The phase separation method involves the separation of the free 
labelled digoxin from the bound using three different techniques:
(i) in the first technique separation is effected by adsorption of 
the free digoxin. Adsorbents used include charcoal, dextran 
coated charcoal, ion exchange resin and talc.
(ii) the second type of separation involves precipitation in which 
the bound antigen is precipiated from the solution by using a 
protein precipitant such as polyethylene glycol or ethanol. A 
second antibody can be used to precipitate the bound primary 
antibody-digoxin complex. This has the disadvantage that it 
requires longer incubation times and additional steps.
(iii) This method uses solid phase antibodies. The solid phase may 
be the inside of a tube wall or antibody conjugated by a 
covalent bond to insoluble inert materials such as glass, or 
plastic beads. After incubation, the contents of the tube are 
centrifuged, the supernatant aspirated and counts are 
performed on the solid phase antibody-antigen complex in the 
bottom of the tube. The coat-a-count and Pharmacia RIA 
digoxin kit uses anti-digoxin antibodies coated on the walls 
of tubes and immobilized on sephadex particles, respectively.
RIA Techniques:
The first RIA method for measuring cardiac glycosides was performed 
on digitoxin [59]. This method required 5ml of plasma and a prior 
extraction step. The assay took 36 hours due to the time taken to 
separate free from bound antibody using second antibody. An improved
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method for measuring digoxin was introduced in 1969 [60] which used 
dextran- coated charcoal to separate the two phases instead of second 
antibody. This assay could be performed with 1ml of plasma within 1 
to 2 hours. Replicate analysis gave a CV of 4% within the digoxin 
range of 0.65-13.0 nmol/L. The antibody used in this assay gave a 
cross- reactivity of 10% with digitoxin. Since the therapeutic range 
of digitoxin is ten times that of digoxin it can also be used to 
measure it [61]. In 1970 a different type of protein digoxin- 
conjugate was used to produce antibody which shortened the incubation 
time to forty minutes [62].
A number of clinical studies were carried out In the early 1970s in 
which it was confirmed that an overlap existed between toxic patients 
and those who were free of symptoms. However, the mean values 
between the two groups were different.
3The problems caused by H-labelled digoxin when used as a tracer
125resulted in the introduction of various I -labelled digoxin 
derivatives using different conjugation procedures. One such method 
[63] was described which used dextran-coated charcoal as phase
separator. This method had a sensitivity of 0.26 nmol/L and required
125a sample volume of 50/il. The I -label using gamma rays shortened
3the assay time to 10 seconds as compared with 3 minutes for H- 
digoxin using ^-radiation. This made emergency assays possible and 
established this type of immunoassay as the method of choice for 
measuring plasma digoxin. A number of papers were published which 
demonstrated the efficacy of digoxin levels in the differential 
diagnosis of patients thought to have toxic levels, resulting in many 
laboratories providing a therapeutic drug monitoring service for
digoxin. Subsequent to this a number of different commercial kits
3 12 5for measuring digoxin, some using H and others I -labelled
digoxin, were introduced. A number of comparative studies involving
RIA kits and other methods for digoxin have been described and are
shown in Table 8.
In recent years, RIA has been modified for automation [64] and speed 
by immobilizing the antibody on a porous pot. The serum sample is 
mixed with a known amount of labelled digoxin and is then passed 
through a column containing the immobilized antibody. Free labelled 
antigen is measured and the bound labelled antigen is released by 
chaotropic agents and quantified.
In RIA,phase separation can cause problems. The use of antibodies 
with high dissociation kinetics of antibody-digoxin complex may give 
erroneous results when used in conjunction with charcoal. This is 
due to the continuous variation in the equilibrium reaction of the 
antibody-digoxin complex caused by charcoal adsorption of the free 
digoxin form. Thus, the bound fraction will decrease with increasing 
exposure to charcoal. Therefore, it is important that charcoal 
contact time be kept constant for digoxin standards and unknown.
Solid phase antibodies cause non-specific binding and alteration in 
reaction kinetics when compared to reactions in an aqueous medium.
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Table 8: Comparison of RIA with other Immunoassay detection systems.
COMPARISON OF RIA WITH OTHER METHODS
Method X Y N S 1 r Reference
CA (RIA) Stratus 108 1.08 0.057 0.968 Dade Data
NEN (RIA) Stratus 58 1.02 0.004 0.964 Dade Data
CA (RIA) Beckman 180 1.07 0.19 0.93 CC.1985:31:929
RIA TDX 84 0.917 0.176 0.96 CC.1988:34:1251
Coming RIA TDX 118 0.91 0.149 0.959 Abbott Data
X - RIA
Y = Other Detection Systems 
N = Number of Patients 
S » Slope 
i = Intercept 
r - Correlation
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In 1987, an RIA method [65] involving a second antibody was described 
in which sheep anti-digoxin antibody is the primary antibody and 
donkey anti-sheep antibody is the precipitating agent. This method 
has the disadvantage that it requires longer incubation times and 
additional steps. Further advantages and disadvantages of RIA are 
summarised in Table 9.
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Table 9: Characteristics of the RÏA method.
(a) Heterogenous method
<b) Sample volume less than 0.5ml
(c) Assay time - 1 hour
(d) Sensitivity - 0.26 nmol/L
(e) Shelf life 6-8 weeks
(f) Radiation hazards
(g) More complicated technically than EMIT
(h) Gamma counter required
(I) Pre-treatment step in some RIA assays only
Ü ) Elimination of DLIFs in RIA not as successful as in EMIT 
[72]
(k) Specificity - digitoxin metabolites may cause interference 
with digoxin antibody
(1) Expensive
69
2.4.2 Enzyme Immunoassays :
EIAs were first used in the detection and quantitation of plasma 
analytes in 1971 [66] . Since that time numerous papers have been 
published describing different types of immunoassays.
The catalytic properties of enzymes enable small quantities of 
digoxin to be measured. The sensitivities of EIAs approach that of 
RIA. The antibody preparation and immunochemical reactions are
similar to RIA only the label and detection method used are 
different.
EIA for digoxin may be subdivided into:
(a) Heterogenous assay types
(b) Homogenous assay types.
(a) Heterogenous Enzymexmmunoassays:
The Du Pont digoxin assay is a heterogenous assay which is based on 
an affinity column mediated immunoassay technique. In this method 
patients' serum is preincubated at room temperature, with an antibody
t
enzyme conjugate consisting of rabbit F(ab ) anti-digoxin antibody 
covalently linked to /3-galactosidase (EC 3.2.1.2.3.). This mixture 
is sampled by the aca III and put through a column in the test pak 
containing ouabain, an analog of digoxin. Free antibody-enzyme 
conjugate is retained, while the bound digoxin antibody-enzyme 
complex passes through to the testpak reaction chamber. Here the 
^-galactosidase portion of the complex catalyses the hydrolysis of
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ortho-nitrophenyl-/S-galactopyranoside to ortho-nitrophenol. The 
change in absorbance at 405nm is directly proportional to serum 
digoxin concentration. This method, in common with nearly all 
immunoassays for digoxin, is affected by DLIFs (Chapter 3). Negative 
interference in 4 patients' samples were reported with this method 
when compared with the TDX and Corning RIA method [67]. Further 
comparisons are shown in Table 10.
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Table 10. Comparison of the DuPont ACMIA Method with other digoxin 
methods.
Method X Y N S i r Reference
ACMIA RIA 29 1.0 -0.21 0.94 CC.1984:30:1012
ACMIA TDX 29 0.942 0.07 0.96 DuPont Data
ACMIA RIA I 119 0.882 0.23 0.954 DuPont Data
ACMIA RIA II 117 0.969 -0.03 0.97 DuPont Data
ACMIA RIA III 84 0.924 0.323 0.952 CC.1988:34:1251
X - RIA
Y = Other Detection Systems 
N = Number of Patients 
S = Slope 
i - Intercept 
r = Correlation
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(b) Homogenous Enzyme immunoassay:
(b.l) EMIT:
In 1975 the first homogenous enzymeimmunoassay for digoxin was 
developed [68] from which the EMIT evolved. The principle method 
used until then was RIA. The EMIT method was evaluated and the 
results compared with an RIA technique using 67 samples. A 
correlation coefficient of 0.979 was obtained between the two 
methods.
Some of the EMIT evaluations are shown in Table 11. They also 
studied the effect of haemolysis on the EMIT assay so as to 
investigate NAD+ reducing enzymes liberated from the red cell which 
might cause positive interference of the NAD+ -linked 
glucose-6-phosphate dehydrogenase. Low digoxin recoveries occured 
only in the presence of gross haemolysis. Moderate haemolysis caused 
no interference. Endogenous glucose-6-phosphate dehydrogenase 
interference is removed because the NAD+ reacts only with the enzyme 
supplied in the assay. In the late 1070s two separate studies 
[69-70] reported good agreement between EMIT and RIA while a third 
[71] study gave interassay precision of 8% and 4% for EMIT and RIA, 
respectively, at a serum digoxin concentration of 1.7 nmol/L. 
However, this latter study gave slightly higher digoxin 
concentrations than RIA with both patients' sera and controls. In 
some assays this is caused by the protein concentration, particularly 
albumin, which can bind both free and labelled digoxin. The bound 
fraction of both albumin and antibody-labelled digoxin [72] shows a
73
false positive increase when the albumin and antibody are in solution 
as with for example charcoal adsorption analysis. Conversely, the 
bound fraction of radiolabelled digoxin decreases when antibody and 
albumin are separated as in the solid phase technique. This is 
caused by albumin combining with labelled digoxin. Errors greater 
than the 25% in apparent digoxin concentration may occur due to 
changes in albumin concentration. Other comparison studies involving 
EMIT are shown in Table 12.
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Table 11. Results of an evaluation study on the EMIT method.
Digoxin Concentration Recovery CV within day CV between day
0.65 nmol/L 105%
3.25 nmol/L 100%
3.9 nmol/L 100%
1.47 nmol/L 3.77%
4.71 nmol/L 2.77%
1.95 nmol/L
8.42%
4.9 nmol/L
5.52%
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Table 12: Comparison of the EMIT method with various immunoassays.
METHOD
X vs Y N S i r Reference
EMIT RIA I 155 1.03 0.10 0.98 71
EMIT RIA 2 170 0.90 0.12 0.97 73
EMIT RIA 3 153 1.09 -0.07 0.98 73
EMIT RIA 4 80 0.96 0.02 0.97 73
EMIT TDX 144 0.95 0.01 0.94 73
EMIT Coming RIA 138 0.99 0.02 0.98 CC.1986:32:1078
EMIT CA (RIA) 134 0.88 0.08 0.96 CC.1986:32:1078
EMIT Immophase RIA 27 0.839 0.581 0.915 Ann Clin. 
Biochem. 1980: 
17:315-318
EMIT Dac-cel RIA 27 1.00 0.47 0.937 Ann Clin. 
Biochem. 1980: 
17:315-318
X = EMIT
Y = Other Detection Systems 
N = Number of Patients 
S = Slope 
i = Intercept 
r = correlation
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In 1984 the EMIT method was adapted for automation which resulted in 
the reduction of the assay time from roughly 30 minutes to 2-5
minutes, thereby increasing the popularity of the method. The use of 
centrifugal analysers resulted In a precision of approximately 8% in 
the therapeutic range. Since the antisera of all immunoassays may be 
able to cross-react with DLIF a pre-treatment step was introduced to 
eliminate such interferences. This involved the addition of a solid 
phase hydrophobic-bonded silica gel extraction step into the EMIT 
assay [73].
When the EMIT assay was compared to six different immunoassay
methods, it gave the best results with little or no interference from
patient samples known to have relatively high concentrations of DLIF
[74]. Therefore, by pre-treatment of the serum with
hydrophobic-linked silica gel chromatography it was possible to
eliminate or significantly reduce digoxin measurements due to
endogenous DLIFs. Further advantages and disadvantages of the
earlier EMIT method are summarised in Table 13.
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T a b l e  1 3 :  S o m e  c h a r a c t e r i s t i c s  o f  t h e  e a r l i e r  EMIT t e c h n i q u e .
(a) Homogenous
(b) Stat capability
(c) Assay-tlme - 5 minutes
(d) Routine enzyme analysers are used
(e) No radiation hazards
(f) Shelf l i f e  - one year
(g) Sample size 50/il
<h) User friendly
CD Run with other assays
(j> S e n sitivity  0.65 nmol/L
<k) S p e cific ity  similar to RIA
(1) Interferences: haemolysis, lipaemla
(m) Kits expensive
(n) Enzyme la b i l i t y
<o) Incubation - 37°C
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( b . 2 )  CEDIA f f n z y m e i m m u n o a s s a y :
The CEDIA assay is based on a genetically engineered /3-galactosidase 
enzyme. This enzyme has been split into two inactive forms using 
recombinant DNA techniques known as EA and ED which can combine 
spontaneously with the formation of active enzyme. The EAs are large 
polypeptides with deletions which are inactive in solution. The EDs 
are small polypeptides containing some of the deletions missing from 
the large polypeptide and are also enzymatically inactive. These 
inactive forms spontaneously recombine to form active enzyme. The 
extent of recombination is determined by the binding of anti-digoxin 
antibodies to the digoxin-labelled peptide which is regulated by the 
concentration of digoxin in the sample.
Method Evaluation:
The CEDIA method was originally evaluated and correlated against RIA
[75] resulting in good agreement having a slope of 1.0 intercept of 
0.06 /ig/1 and correlation of 0.97. More recent comparisons against 
other digoxin methods are shown in Table 14. No comparison studies 
against the EMIT method have yet been published.
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Table 14: Comparison of CEDIA with other methods for Digoxin
measurement.
METHOD
X vs Y N S i r Reference
CEDIA TDX 61 1.08 -0.20 0.93 CC.1986:33:1014
CEDIA CA (RIA) 15 0.99 0.232 0.935 CC.1988:34:1249
CEDIA RIA 84 0.95 0.115 0.959 CC.1988:34:1251
CEDIA RIA 1.03-1.07 0. 954-0.967 CC.1988:34:1209
CEDIA RIA 90 1.0 0.06 0.95 CC.1990:36:560-561
X -  CEDIA
Y = Other Detection Systems 
N = Number of Patients 
S = Slope 
i  = Intercept 
r = correlation
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Light waves by conventional sources are oriented randomly Figure 9. 
plane polarized light is  lig h t whose vibrations take place in only 
one of these possible planes [76]. Ordinary ligh t is  turned into 
plane blue polarized l ig h t  as in the TDX FPIA method by passing i t  
through a f i l t e r  and a liquid crystal polarizer.
Figure 9:
2 . 4 . 3  Fluorescent Polarization Inmmoassay:
Ordinary Light Polarized Light
When the fluroescein molecule is excited by polarized blue lig h t,  the 
size of the molecule w ill  determine whether polarized green or 
non-polarized green lig h t is emitted. I f  the fluorescein molecule is  
large the rotational relaxation time is longer than, the fluorescence
l
decay time causing the emission of plane polarized green lig h t,  
p arallel to the excitation blue polarized ligh t. A small fluorescein  
molecule, on the other hand, causes the emission of non-polarized 
green lig h t  due to its  rotational relaxation time being faster than 
the fluroescence decay time. When such a small fluorescein molecule 
is  attached to a large molecule as in a flurescein-labelled  
antigen-antibody complex plane polarized lig h t w ill  be emitted. This
phenomenon Is used in TDX immunoassay methods for the quantitation of 
serum digoxin.
The prinicple of the FPIA TDX method is the competition between the 
digoxin in the sample and a known amount of fluorescein-labelled 
digoxin for a limited number of antibody binding sites. The amount 
of fluorescein- labelled digoxin combining with antibody is inversely 
proportional to the serum digoxin concentration. Therefore, if the 
amount of serum digoxin is small the degree of polarization 
increases. The converse occurs if the analyte in the sample is high.
This method has a pre-treatment step in which an equal volume of 
sample is mixed with an equal volume of sulphosalicylic acid in 
methanol to precipitate serum proteins before the immunoassay so as 
to minimize the native background fluorescence produced by serum 
proteins, thus resulting in a more favourable signal to noise ratio.
A number of evaluation of the FPIA have been performed. One such 
method involved comparing FPIA with the Amerlex RIA digoxin assay 
[77]. Table 15 compares the precision of the two methods. Among the 
advantages this method has over RIA includes assay time of 14 minutes 
compared to 3 hours with the Amerlex RIA. It has a shelf-life of one 
year, as against 4-8 weeks for RIA, and a safer tracer is also used. 
Comparison studies of FPIA with other methods were generally good 
(Table 16). However, in some studies the mean serum digoxin 
concentrations were 10-14% lower than those of RIA with a decrease in 
serum digoxin by 8% for every 10 g/1 increase in serum proteins [78]. 
These falsely low results were due to the difference in protein
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concentration between the standards used for calibration and that of 
the samples. The protein concentration of the standards used in the 
kit was 50 g/1 and that of the samples normally 60-80 g/1. During 
the pre-treatment step the magnitude of the binding of serum digoxin 
is related to the protein concentrations with more digoxin binding to 
samples containing higher serum proteins than those with lower 
concentrations causing a reduction in digoxin concentration in the 
supernatant. By adjusting the FPIA standards to protein
concentrations similar to those of the samples resulted in the 
elimination of this bias and good correlation between FPIA and RIA 
methods. Therefore, for accurate results using the FPIA technique 
digoxin standard should be prepared in a matrix with a total protein 
concentration similar to that of the patients.
Abbott recently modified the TDX [79] method and called it TDX II so 
as to reduce interference from DLIF. These were almost eliminated in 
either renal or hepatic failure but appreciable concentrations were 
measured in patients with both hepatic and renal failure and in 
neonates.
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T a b l e  1 5 :  P r e c i s i o n  e v a l u a t i o n  o f  t h e  F P I A  a n d  A m e r l e x  R IA  a s s a y .
METHOD DIG. CONC. (NMOL/L) CV% WITHIN RUN CV% BETWEEN RUN
FPIA 0.79 6.8 8.5
RIA 0.81 2.9 8.5
FPIA 2.12 2.7 4.1
RIA 2.43 3.8 6.0
FPIA 3.16 2.2 3.7
RIA 3.34 4.4 5.1
Table 16: Comparison of the FPIA with other immunoassays.
METHODS
X vs Y N S i  r Reference
FPIA CA RIA 109 0.902 0.083 0.950 Abbott Data
FPIA Beckman 172 1.08 0.05 0.94 CC.1985;31;922
FPIA Stratus 60 1.04 0.10 1.0 CC.1985;31;922
FPIA RIA 84 0.917 0.176 0.96 CC.1988;34;1251
FPIA Du Pont 25 1.03 0 .01 0.96 CC.1985;31;928
X = FPIA
Y = Other Detection Systems 
N = Number of Patients 
S = Slope 
i  = Intercept 
r = correlation
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2 . 5  SALIVARY DIGOXIN:
It has been suggested that drug concentration in saliva is a good 
approximation of the non-protein fraction. Many workers have 
reported different mean ratios between salivary and serum digoxin 
(Table 17). The first such study for the determination of digoxin in 
saliva involved an extraction step followed by RIA of the extract 
[80]. Since direct measurement of salivary digoxin with RIA gave 
imprecise results an extraction step was required. The method was 
then found to be suitable for monitoring salivary digoxin. Most of 
the other reports [81, 83, 85, 86, 87] have recommended the use of 
salivary digoxin estimation as an alternative to that of serum 
digoxin with one author recommending its usefulness in 
pharmacokinetic studies. Van Der Vijgh [82] had reservations about 
its use in therapeutic drug monitoring and recommended measuring at 
least one saliva/serum ratio in each patient. He concluded by stating 
that serum digoxin monitoring was more reliable than that of saliva. 
However, two sets of workers [85, 89] have shown inter-individual
variation in saliva/serum digoxin ratio. This variability in the 
saliva/serum digoxin ratio resulted in the rejection of saliva for 
therapeutic monitoring of serum digoxin by one research group [86],
There are wide inter-individual differences in protein and receptor 
binding of digoxin in different disease states (e.g. renal failure). 
It would appear, therefore, that measurement of the free fraction as 
measured in saliva would be a more effective method for assessing 
individual therapy if a suitable therapeutic range could be 
established for a specific disease state.
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T a b l e  1 7 :  P r e v i o u s  e v a l u a t i o n s  o f  s a l i v a / s e r u m  d i g o x i n  r a t i o s .
INDIVIDUALS
STUDIED
SALIVA/SERUM
RATIO
S.D. p SALIVA/ 
SERUM r
REF
Hospital patients 0.78 ±0.7 <.001 0.99 80
Hospital patients 1.14 ±0.48 <.001 0.90 81
Hospital patients 1.7 0.90 82
Healthy adults 1.34 ±0.34 < .01-<.05 0.88-0.63 83
Healthy adults 1.25 ±0.41 <.001 0.90 84
Hospital patients 1.25 ±0.14 0.90 85
Infants 0.66 ±0.20 <.001 0.71 86
Hospital patients 0.67 ±0.10 0.96 87
Healthy patients 0.55-0.63 1+ O 0
 
o\ 1
COoO 87
S.D. » Standard Deviation 
P = Probability  
r = Correlation coefficient
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C h a p t e r  3
As already stated one of the problems associated with serum digoxin
assays has been the presence of endogenous factors which gave false 
positive results. These substances were first reported in 1965 
[88-89] using an assay based on the inhibition of rubidenium uptake 
by human red cells. It was quickly noticed that the discrepancies in 
assays (as much as 3.9 nmol/L) could not be accounted for by digoxin 
metabolites [90], interfering drugs or serum protein concentration 
[91] . In studies performed apparent serum digoxin levels as high as 
13 nmol/L [89] have been reported in subjects not on digoxin therapy 
nor any drug known to interfere with the assay. This may explain the 
overlap in therapeutic and toxic ranges that occurs in some patients.
The nature of DLIF is still unclear but it appears that it is mostly 
protein bound (greater than 90% in normal people) and, unless 
concentrated, is not detectable in serum of normal people using 
immunoassays. It is a water soluble [92], neutral molecule not 
possessing carboxylic or primary amino groups with an approximate 
size of less than 1,000 daltons. A suggested hypothesis [92] is that 
DLIFs are present in serum in three forms:
(i) tightly but non-covalently bound
(ii) weakly bound
(iii) free form.
D IG O X IN -L IK E  IMMUNOREACTIVE FACTORS
8 7
DLIFs are divided into two groups:
(a) those that interfere only in digoxin immunoassay e.g. oestrogens, 
progesterone, lipids and bile salts [90-91].
(b) those that inhibit Na+/K+ ATP-ase.
The latter group includes those substances that have been postulated 
to act as natriuretic hormones in essential hypertension. The 
observation of a natriuretic factor that appears in the blood after 
acute volume expansion and inhibits Na+/K+ ATP-ase dates back many 
years. In 1961 blood was cross-circulated between two dogs, in which 
intravascular volume of one was expanded causing natriuresis in the 
other [93], From 1974-1976 a number of studies suggested that this 
natriuretic factor [93-94] was an inhibitor of Na+/K+ ATP-ase and 
sodium transport. It was shown that this inhibitor of Na+/K+ ATP-ase 
cross-reacted with antibodies to digoxin [95]. In addition, recent 
studies using serum immunoassays have indicated the presence of 
digoxin in subjects not receiving the drug during oral salt loading 
[95] during the third trimester of pregnancy [ 9 6 ], in newborn infants
[97] and in patients with renal impairment [ 9 8 ] .  Earlier studies 
showed that red cells from patients with uremia had an increased 
intracellular sodium concentration and reduced membrane Na+/K+ 
ATP-ase activity. These abnormalities could be induced in normal 
cells by incubating them in plasma from patients with uremia.
The evidence for an inhibitor of the Na+/K+ ATP-ase pump in the 
plasma of some subjects with low renin hypertension is more recent. 
This has been demonstrated by a method which involves incubation of
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normal red cells in plasma from hypertensive subjects followed by 
measurement of Na+/K+ pump activity. Intravenous injection of 
antibodies [99] to digoxin has been observed to lower blood pressure 
in two animals with low renin hypertension. Inhibition of Na+/K+ 
ATP-ase has also been reported at the cell and tissue levels in 
animals and patients with hypertension, especially low renin 
hypertension. The natriuretic hormone that appears after acute 
volume expansion and inhibits Na+/K+ ATP-ase appears to be a heat 
stable small molecule attached to a protein. The hormone may come 
from the hypothalamus; in fact, experimental lesions of the 
hypothalamus decreases its level in the blood. This might suggest 
that the hypothalamus simply influences the secretion of the factor 
from another source such as the adrenal glands. This would support 
the idea that it is a steroid similar to digoxin which is known to 
bind to Na+/K+ ATP-ase.
As mentioned, DLIFs have been found in neonates and amniotic fluid 
even when neither the child nor the mother have been given digoxin. 
These values ran as high as 1.82 nmol/L and were detected in 90% of 
infants. A study involving 24 premature infants [100] found that all 
of them had levels >0.78 nmol/L as measured by the NML RIA kit (range 
0.78-6.89 nmol/L). Detectable levels of DLIF may remain in the serum 
for up to 2 weeks post-partum and reaches a maximum at the 4th day. 
In 1983 a study of DLIFs in neonates found that within day variation 
was small, but between day variation was appreciable for 2 weeks 
post-partum. This suggests that it is not possible to determine an 
"apparent digoxin concentration" base line due to DLIF prior to 
commencing digoxin therapy [101].
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DLIF increases in serum through pregnancy and reaches a peak in the 
third trimester. Levels of DLIF in the serum of pregnant women have 
been shown to range from 0.13 to 0.78 nmol/L with serum 
concentrations in hypertensive pregnant women reaching higher values 
during this time which may cause clinical problems. DLIF values 
decline rapidly in these women after parturition.
Similar high DLIF concentrations have been found in renal or hepatic 
failure studies. In a study of patients with renal failure but not 
on digoxin, "apparent digoxin values" as high as 1.3 nmol/L were 
noted. The "apparent digoxin concentration" was not related to the 
degree of renal impairment nor the haemodialysis state of the patient 
[98] . Different immunoassays also varied in "apparent digoxin 
concentrations" measured from any one specimen. In another study
[98] on two groups of patients one in renal failure and the other 
having normal renal function, variable results were shown between the 
immunoassays in the renal dysfunction groups when compared with those 
from the normal renal function group. A study [102] performed on one 
patient in acute renal failure who was on digoxin showed that the 
serum digoxin increased for 10 days after the last dose. Different 
immunoassays gave different digoxin values when used to measure this 
specimen.
DLIFs have been reduced or eliminated from interfering in digoxin 
immunoassay measurements using pre-treatment procedures such as:
(i) ultrafiltration
(ii) altering immunoassay incubation times
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(iii) combining H.P.L.C. with RIA
(iv) boiling
(v) TCA
In 1986 [103] it was postulated that DLIFs in the serum of normal
individuals, patients in renal failure, pregnant women and neonates 
are mainly highly protein-bound. The increased concentrations of 
DLIF immunoreactivity with the last three groups are not due to 
increased concentrations of unbound factors, but rather to changes in 
protein binding which results in more loosely bound protein DLIF in 
the serum. This enables digoxin antibodies to remove more DLIF from 
the protein binding sites. This finding that DLIFs are largely 
protein-bound suggested that DLIF and their effects on immunoassays 
can be decreased or eliminated by removing serum proteins. These 
pre-treatment steps should not disrupt the DLIF protein binding e.g. 
in protein precipitation with TCA significant amounts of DLIF are 
left in the samples due to this disruption. In 1987 a method which 
substituted ultrafiltration for precipitation with sulphosalicylic 
acid resulted in complete elimination of DLIF using the Abbott TDX 
FPIA method [104]. By increasing the incubation time from 30-60 
minutes DLIFs were reduced by 68% in patients with renal failure, 
pregnant women and from chord blood. Increasing the incubation time 
from 30-120 minutes decreased the DLIF by a mean of 67% within a 
range of 31-100%. The explanation for this phenomenon is thought to 
be due to the fact that the antibody reaction with DLIF has not 
reached equilibrium at the end of the stated incubation time. They 
succeeded in eliminating 89% of DLIFs in a sample using a 20 minute 
ultrafiltration step. By combining increased incubation and ultra­
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f i l tr a tio n  [103] DLIF a c t iv ity  was completely eliminated. Boiling  
the sample resulted in 60% DLIF removal and precipitation with TCA 
resulted in 33% removal. In 1985 [47] a study involving 50 people on 
digoxin was performed combining small column extraction of serum with 
HPLC and RIA of the eluent. I t  was successful in resolving the 
digoxin peak from i t s  metabolites with the exception of 
dihydrodigoxin which co-eluted with digoxin.
The results of these studies show that a very sp ecific  method is  
needed for the accurate measurement of digoxin. In view of this, an 
investigation of the effects of DLIF and other interferents on the 
CEDIA and EMIT methods w ill  be of great significance in Part 2 of 
this thesis.
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PART 2
C h a p t e r  4
INTRODUCTION
The clinical importance of measuring serum digoxin for therapeutic 
drug monitoring has been recognised [60,62,68]. Digoxin is the most 
widely requested drug in our laboratory and in view of its narrow 
therapeutic range and virtual total elimination from the body via the 
kidneys, it is important that it be specifically measured in patients 
with any degree of renal impairment. This measurement is now routine 
in many clinical chemistry laboratories, involving a large number of 
different methods.
Chromatography (e.g. TLC, HPLC) is successfully used in the 
measurement of most drugs. Optical methods of detection used are 
generally insufficiently sensitive for digoxin because of its low 
concentration in serum. While these constraints can be overcome by 
using large serum sample volumes of up to 5 mis, this renders it 
unsuitable for neonate samples. When other factors such as quick 
turn-around time (e.g. for clinics or intravenous infusions), the 
ability to handle relatively large batches, the need for high 
precision and the overall cost of setting up and maintaining such a 
service are considered, the suitability of chromatography by itself 
is limited.
Studies have shown similar correlations between bioassays and 
immunoassays. Bioassays are specific for cardioactive glycosides but 
are limited by problems with sample size, reproducibility and
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specificity. The method is cumbersome, time consuming and labour 
intensive which renders it unsuitable for digoxin estimation.
FPIA is a rapid and sensitive method. The sensitivity and 
specificity depends both upon the labelled digoxin (e.g. with 
fluoroscein providing the emitted light) and with the characteristics 
of the antibody used. The presence of interfering endogenous 
fluorophore substances in biological samples necessitate the use of 
an extraction step. As already discussed, this latter step can lead 
to erroneous digoxin results due to protein concentration differences 
between the standards used and the serum samples. The measurement of 
reaction kinetics in these samples requires the use of special 
instrumentation, thus incurring extra expense.
Radioimmunoassays are, by nature, heterogenous [60,62], Since the 
bound and free labelled drug emits a similar signal, these must be 
separated to determine serum digoxin. Assays are available which 
measure either the bound or free labelled drug. Separation of the 
bound from free labelled drug may be accomplished by adsorption of 
the free drug onto solid particles (e.g. charcoal) followed by 
measurement of the radioactivity of the bound labelled drug in the 
supernatant. Problems may arise due to incomplete adsorption of the 
free drug and trapping of some bound drug onto the charcoal . These 
problems may be substantially reduced by using either antibodies 
bound to solid phases such as the assay tube or magnetic particles. 
However, solid phase based immunoassays have traditionally been 
plagued by non- specific binding to the solid phase and by slow 
reaction kinetics relative to reactants that are free to diffuse in
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solution. RIA methods are generally more sensitive than enzyme 
immunoasssays.
The concentrations in which digoxin can occur in serum are such that 
the detection need not be very sensitive. Although RIA methods also
possess speed, specificity and sensitivity, they have the
disadvantage associated with all radioisotopic methods, namely, 
radiation hazards, decay of radio-labelled reagents, the need for 
radioactive counting equipment and disposal problems. The shelf-life 
of most RIA reagents is only 6-8 weeks as against one year for the 
CEDIA or EMIT methods. Therefore, infrequent use of RIA is
uneconomical because of the limited shelf-life of the label.
The CEDIA and EMIT methods chosen for evaluation in this study are 
homogeneous enzyme immunoassays. In these assays, there is no need 
to separate bound from free as the optical signal differs from 
antibody-bound-labelled drug and free labelled drug. Consequently, 
measurement can take place in a single cuvette. This results in
decreased reagent cost, reduces technical labour, avoids some sample 
handling, permits the use of currently available enzyme analysers, 
thus facilitating data transfer. More importantly, it can be 
included in a biochemical screening profile with a single instrument. 
The two assays chosen are relatively simple and fast to perform by 
anyone trained to do routine enzyme analyses. This could enable 
personnel "on call" who cover many areas within the laboratory to 
perform the test accurately and quickly. Both assays are performed 
at 37°C and involve two pipetting steps and a number of absorbance 
readings. Since most assays, including digoxin measurement are
performed at 37°C on the enzyme analyser, there is no time delay for 
temperature adjustment using these methods.
One problem associated with immunoassays for digoxin is the 
specificity of the antibody as there maybe interference from 
non-specific binding due to the digoxin metabolites and endogenous 
DLIFs. The DLIFs present in certain clinical groups, interfere to 
varying degrees with most immunoassays. Recent studies have also 
shown linoleic, arachidonic, linolelaidic and 1-mono- linolenoyl 
glycerol as compounds likely to contribute to DLIF activity in plasma 
[105, 58]. This indicates the importance of evaluating each
immunoassay for DLIF interference. A suitable pre- treatment step 
should eliminate or greatly reduce the concentration of DLIF in serum 
before digoxin is measured with the advantage that a less specific 
antibody could then be used for accurate measurement of the drug.
The EMIT method uses a pre-treatment procedure involving the addition 
of a solid phase hydrophobic-bonded silica gel extraction step into 
the assay. The effectiveness of this step is being investigated in 
this study. Since the CEDIA method uses no sample pre-treatment step 
the specificity of the antibody for digoxin must be investigated.
The prinicple of the EMIT method involves an NAD+-linked glucose-6- 
phosphate dehydrogenase step. It was important to investigate the 
possible release of NAD+ reducing enzymes from the red cell and also 
the spectrophotometric effect of haemolysis on each method [68],
The total protein concentration of the plasma is about 70-75 g/1.
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Albumin is the most abundant protein, representing 55-65% of the 
total fraction. Holtzman et al [106] studied the effect of different 
albumin concentrations on the binding of a radiolabelled antigen to 
antibody. The results showed that the binding of the labelled 
digoxin to the antibody is very sensitive to variations in albumin
concentration. Therefore, using both kits, it was decided to examine
this variable. The spectrophotometric effect of bilirubin on each 
method was also studied.
The use of saliva to determine certain drug concentrations has been 
shown to give a reliable indication of their concentrations in 
plasma. It is generally accepted that the non-protein bound or free 
fraction of a drug exerts the pharmacological effect and that
ideally, estimation of this fraction would yield the most useful 
indication of effective therapy. The extent of protein binding 
determines the distribution of digoxin between the various fluid 
compartments and the receptor site. Only non-protein bound digoxin 
may move from the vascular compartment to the site of action.
Interpretion of total drug concentrations become difficult in 
situations where there is abnormal binding of the drug. In the body, 
about half the total digoxin is bound to skeletal muscle and 
approximately 25% of serum digoxin is exclusively bound to serum 
albumin. However, bound fractions from 18-33% have been reported 
suggesting that the ratio is not as constant as claimed [25]. In 
plasma, the ratio of free to total bound drug varies with age and 
disease state. In the plasma, any variations in the albumin 
concentration will cause changes in protein binding. Digoxin may 
also be displaced from albumin by molecules sharing the same binding
site or by drugs administered concomitantly.
Interpretation of total digoxin concentration is also difficult in 
renal failure where there is some evidence that toxicity may be more 
likely to occur at plasma digoxin concentrations not normally 
associated with toxicity. In these situations, salivary digoxin 
measurements may yield more meaningful results than serum digoxin. In 
this study, the efficacy of the CEDIA and EMIT assays are 
investigated for salivary digoxin measurement using saliva/serum 
ratios and correlations. The modified procedures for each kit are 
used to investigate the possible presence of DLIFs in saliva.
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C h a p t e r  5
MATERIALS AND METHODS
5.1 MATERIALS:
5.1.1 EMIT Column Digoxin Assay:
(a) EMIT column digoxin assay 250 test kit; Cat. No. 6H019 UL.
(b) EMIT column digoxin calibrators, lyophilised 6 x 3ml ;
Cat. No. 6H109 UL.
(c) Syva solid phase columns, system II, 100 columns;
Cat. No. 6H029 UL.
(d) EMIT column digoxin mobile phase solution, 60% methanol in 
diluted water; 3 x 100ml
Cat. No. 64039 UL.
EMIT digoxin reagents manufactured by Syva Co., Palo Alto, CA.
(e) CEDIA digoxin assay - CEDIA digoxin assay kit, 100 test size; 
Cat. No. 80-300-30.
CEDIA digoxin reagents manufacured by Microgenics Corp., CA.
(f) 1 gram of Digoxin;
Cat. No. 80469 TM - Aldrich Chemical Co., P.O. Box 355,
Milwall, W1 53201.
(g) Albuminar-20 (human serum albumin 20% w/v)
Each bottle contains 20g of human serum albumin per 100 ml. 
Manufactured by: Pharma GmBH Eschwedge, West Germany.
(h) Buffered phosphate saline pH 7.3 approx. 100 tablets.
L o t  N o .  R 0 0 0  6 7 5  0 0 1  -  O x f o r d  L t d . ,  U . K .
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Sigma Chemical Co. Ltd. 
(j) 0.1 molar HCL.
5.1.2. C o n t r o l  S e r a :
( i )  P y r i d i n e ,  1 0 0 0 m l .
Gilford tri-level TDM controls, TDM 701 Ciba Corning Diagnostics
Level I Lot No. 075701 1.9 ± 0.4 nmol/L
Level II Lot No. 076701 3.1 ± 0.6 nmol/L
Level III Lot No. 077701 4.2 ± 0.8 nmol/L.
5.1.3. E q u ip m e n t :
Cobas Bio Centrifugal Analyser, Hoffman La Roche, Switzerland.
Vac Elut System (vacuum extraction box), Analytichem International, 
CA, USA.
Vacuum Pump 
Vacuum Tubing 
Syva Vacuum Receiver
Coulter T-890 and Coulter Mixer, Coulter Electronics Ltd., England. 
Water bath, type 586, Grant Instruments Ltd., Cambridge.
Visking Dialysis Tubing type 12 (3/4 inch diameter), Mediceli
International Ltd., 239 Liverpool Road, London N11LX.
Teflon Cell - Type A, Polypenco Ltd., Engineering Parts Division,
P.O. Box 56, 83 Bridge Road East, W.G. City, Hertfordshire, Al 71LA, 
England.
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Oertling pan-balance Mode R-20, 200 g capacity, 100 ml graduated 
Vortex Mixer
adjustable Oxford pipette
adjustable Oxford pipette
adjustable Oxford pipette
adjustable Oxford pipette
200 - 1000 /il adjustable Oxford pipette
1 - 5 ml adjustable Oxford pipette
0.5 - 10 /il 
10 - 20 /il 
0 - 50 /il
0 - 200 /il
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5 . 2  EMIT COLUMN DIGOXIN ASSAY:
5.2.1. Reagents:
Reagents for the measurement of plasma digoxin are supplied in the 
kit as follows:
(a) Reagent A:
Lyophilised material reconstituted with 3.0 ml of distilled 
water. It contains:
(1) Gamma globulin fraction from rabbit immunized with digoxin
(2) NAD
(3) Glucose -6-phosphate
(4) 0.055M TRIS HCL, pH 7.5
(5) 0.5% w/v Sodium azide as preservative
(6) Bulking agents and stabilizers
(b) Reagent B:
Lyophilised material reconstituted with 15 ml of distilled 
water. It contains:
(1) Digoxin covalently bound to glucose-6-phosphate 
dehydrogenase
(2) 0.55 molar TRIS HCL, pH 7.5
(3) 0.05% w/v Sodium azide as preservative
(c) Buffer Concentrate:
Supplied in liquid concentrate form - volume 13.3 ml. It 
contains:
(1) 0.83 molar TRIS buffer, pH 8.0
1 0 3
(2) 0.075% w/v Sodium azide as preservative
(3) Bulking agents and stabilizers
5.2.2. C a l i b r a t o r s :
6 x 3 ml lyophilised serum based calibrators containing 0.0, 0.64, 
1.28, 2.56, 3.84 and 5.12 nmol/L digoxin. Stability is 3 months when 
stored at 2-8°C.
5.2.3. P r e p a r a t i o n  and  S t o r a g e  o f  Work i n g  R e a g e n t s :
(a) Reagent A:
One part of reconstituted Reagent A was mixed with 11 parts 
of buffer solution. It was stored at 2-8°C and was stable 
for 3 weeks.
(b) Reagent B:
It was used as reconstituted.
(c) Buffer Solution:
It was diluted to 133ml with distilled water for use.
Stability was 12 weeks when stored at room temperature.
5.2.4. EMIT E x t r a c t i o n  S t e p :
This procedure is used to separate digoxin from serum, plasma or 
saliva. Sample was passed through a disposable Syva solid phase 
column, containing covalently-linked silica gel which adsorbs digoxin 
[73]. Hydrochloric acid followed by water elutes all other 
substances except digoxin from the column. The EMIT column digoxin 
mobile phase solution is used to elute digoxin from the column into a
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test tube. The extract is capped, briefly vortexed and the
concentration of digoxin determined by the EMIT assay.
5.2.5. E x t r a c t i o n  P r o c e d u r e :
(1) The vacuum pump was set at 10-15 in.Hg-sufficient to draw 1ml 
of water in 15-25 seconds.
(2) The solid phase columns were inserted into ports on the vacuum 
manifold lid. Any unused holes were plugged.
(3) 350 ml of mobile phase solution was pipetted into each column to 
"condition" the stationary phase. The vacuum was then applied 
until the mobile solution had completely washed from the column. 
The vacuum was then released.
(4) 0.5 ml of either sample, control or calibrator was pipetted into 
each column. The vacuum was applied to allow the specimen to 
completely aspirate through the columns. The vacuum may remain 
on.
(5) 1.0 ml of 0.1 N HC1 was added to each column. The vacuum was 
applied and the solution was aspirated through the columns.
(6) With the vacuum still on, 1.0 ml of distilled water was added to 
each column and aspirated. The vacuum was maintained for an 
additional 10 seconds to ensure that no liquid remained in the 
probes.
(7) The vacuum manifold lid was removed and the probes on the under­
side were wiped dry. 10 x 75 mm test tubes (only this size 
suitable) were labelled for each sample and placed in a rack 
under each column port. The vacuum lid was then tightly 
replaced.
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(8) 350 ml of mobile phase solution was pipetted into each column.
The vacuum was applied until the solution had completely 
aspirated through the columns into the test tubes. The vacuum 
was maintained for an extra 10 seconds to ensure complete 
removal of solution. The vacuum was not left on for more than 1 
minute so as to avoid eluent evaporation. The vacuum manifold 
lid was removed. The tips of the probes were tapped against the 
test tube walls to recover any remaining solution. Each tube 
was then thoroughly mixed for 3-5 seconds. The tubes were 
capped immediately to avoid evaporation. Any eluate stored for 
greater than 1 hour was mixed. When properly sealed the eluate 
may be stored for one week at 2-8°C.
5.2.6. EMIT Assay Principle:
EMIT is a homogenous enzyme immunoassay system and is quite easily 
automated. The EMIT method (Figure 10) employs a bacterial 
(Leuconostoc mesenteroides) enzyme glucose-6-phosphate dehydrogenase 
covalently linked to digoxin. The linkage is made close to the 
active site of the enzyme such that combination of the conjugate 
complex to the antibody inhibits enzyme activity. Free digoxin in 
the sample reverses the inhibition by competing with enzyme-labelled 
digoxin for a limited number of antibody binding sites. The enzyme 
activity of the conjugate is proportional to the concentration of the 
free drug. The antibody probably inhibits the enzyme activity by 
inducing or preventing certain conformational changes at the active 
site of the enzyme. Glucose-6-phosphate dehydrogenase activity is 
measured spectrophotometrically at 340 nm due to the production of
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NADH corresponding to plasma digoxin concentration.
5.2.7. EMIT Assay Procedure:
The parameter l is t in g  for the EMIT method is  shown in Table 18.
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1. Active enzyme.
2. The addition of the digoxin-specific antibody Inhibits the enzyme
by inducing or preventing conformational changes necessary for
enzyme activity.
3. Dlgoxin in patients serum modulates enzyme activity. Active
enzyme converts NAD* to NADH, resulting in an increase in absorb­
ance that is measured at 340nm.
ACTIVE e :e y m e
Enzyme 
l e t t r e  'S i te  
Dlgoxin
F i g u r e  1 0 :  P r i n c i p l e  o f  t h e  EMIT H o m o g e n o u s  A s u j  S y s t e m .
INACTIVE ENZTME
ACTIVE ENZYME
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assay and CEDIA digoxin assay.
T a b l e  1 8 :  C o b a s  B i o  p r o g r a m m i n g  f o r  t h e  S y v a  EMIT c o l u m n  d i g o x i n
EMIT
« Reaction direction/test name
CEDIA
11;44;49;47 (+ Digoxin)
1 Units 14(nmol/L) 14 (nmol/L)
2 Calculation factor 3700 3333.3
3 Standard 1 0.0 0.0
3 Standard 2 0.64 2.56
3 Standard 3 1.28 5.12
3 Standard 4 2.56
3 Standard 5 3.84
3 Standard 6 5.12
6 Limit 0 0
7 Temperature 37°C 37°C
8 Type of analysis 7.3 3
9 Wavelength (nm) 340 420
10 Sample volume /il 30 25
11 Diluent volume /il 60 10
12 Reagent volume y. 1 115 120
13 Incubation time sec. 100 10
14 Start reagent volume /il 45 75
15 Time of 1st reading sec. 5.0 700
16 Time interval sec. 10 10
17 Number of readings sec. 25 21
18 Blanking mode 0 0
19 Printout mode 0/1 2
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5 . 2 . 8 .  Explanation of Parameters:
A Cobas Bio centrifugal analyser with standard "Dens" software was 
used. "Dens" is an acronym for data evaluation for non-linear 
standard curves. It is possible to construct a new curve, store a 
curve in memory or correct a stored curve using a single calibrator. 
The Cobas Bio sample disc contains twenty five sample positions and 
the cuvette rotor contains twenty-nine cuvettes. This allows 
analysis of eleven patient samples and three controls in each batch 
(duplicates).
(a) Type of Analysis 7.3:
This type of analysis enables "Dens" software to process non­
linear data reduction of kinetic enzymatic assays with start 
reagent.
(b) Blanking Mode 0:
This permits water to be used as a blanking solution.
(c) Printout Mode 0:
Printout mode 0 evaluates samples against a stored curve.
(d) Printout Mode 1:
The Cobas Bio automatically calculates a calibration curve using
math model no. 1, a four parameter logit function.
Logit function:
R = R + K z— —----f— ——r t-t-o o 1 + exp[-(a+bc)]
where: R = response (rate of change of absorbance) 
c = concentration 
a and b = non-linear coefficients 
R = zero standard responseO
K = scale parameter
C
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The run is calibrated using math model, no. 2, a five parameter 
logit fit. Absorbance data was obtained from the instrument by 
changing "Type of Analysis 7.3" to "3" and by changing the 
"Printout mode" to "2".
( e )  P r i n t o u t  M ode 2 :
I l l
5.3 CEDIA D ig o x in  A ssa y :
5.3.1. R e a g e n ts  :
Reagents for the measurement of plasma digoxin are provided in vials 
in each kit as follows :
(a) Enzyme-Donor :
Lyophilised material reconstituted with 10 ml of ED
reconstitution buffer. It contains:
(1) ED covalently bound to digoxin
(2) Buffer salts
(3) 0-ni tropheny1-fi-D-galac topyrano s ide
(4) 0.5 mg sodium azide as preservative.
(b) Enzyme-Ac c ep to r:
Lyophilised material reconstituted with 16 ml of EA
reconstitution buffer. It contains:
(1) Enzyme-acceptor
(2) Digoxin-specific antibody
(3) Buffer salts
(4) 0.8 mg sodium azide as preservative.
(c) Enzyme-Donor Reconstitution Buffer:
(1) Phosphate buffer - volume 11 ml
(2) Stabilizers and 20 mmol/1 sodium azide as preservative.
(d) Enzyme-Acceptor Reconstitution Buffer :
(1) Phosphate buffer - volume 17.0 ml
(2) Stabilizers and 20 mmol/1 sodium azide as preservative.
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5 . 3 . 2 .  Digoxin Calibrators:
Serum based calibrators containing 0.0 nmol/1 (volume 4.5 ml) 2.56 
nmol/1 (volume 3.0 ml) and 5.12 nmol/1 (volume 3.0 ml) were supplied 
with each kit. These calibrators were supplied in liquid form and no 
reconstitution was necessary. All reagents and calibrators were 
stored at 2-8°C.
5.3.3. CEDIA Assay Theory:
The CEDIA immunoassay for the quantitative measurement of digoxin 
utilises a new concept in enzyme immunoassay [75], A new homogenous 
enzyme immunoassay has been developed by the genetic engineering of 
/9-galactosidase (EC 3.2.1.2.3.), an enzyme commonly used in enzyme- 
linked immunoassays. The lac operon of E. coli consists of (0) 
operator, (F) promotor and Z, Y, A genes (Figures 11 and 12). The Z 
gene encodes for a large enzymatically inactive polypeptide 
consisting of 1021 amino acids which spontaneously associate with 
other similar polypeptides into a tetrameric form which is the active 
^-galactosidase. The large polypeptide is formed as a result of the 
transcription of the DNA in the Z gene to mRNA and the translation of 
this information into the polypeptide. Using recombinant DNA 
techniques EAs and EDs were constructed. The EAs are large inactive 
polypeptides having small deletions or missing sequences in the 
encoded proteins. The EDs are small inactive polypeptides containing 
some of the sequences omitted from the EAs. The EAs and the EDs are 
both enzymatically inactive but spontaneously associate in solution 
to form fully active tetrameric enzymes similar to natural 
/3-galactosidase. This recombinant DNA technique has been used by
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Microgenic Corporation to produce families of EAs and EDs which has 
allowed the development of CEDIA homogenous assays.
5.3.4. CEDIA Assay Principle:
The CEDIA homogenous immunoassay system operates by regulating the 
spontaneous association of the EDs and EAs through an 
antibody-antigen reaction. A single digoxin moiety is covalently 
attached to each ED molecule so that binding by anti-digoxin 
antibodies inhibits the reassociation of EA and ED fragments. The 
digoxin in the patients sample competes with the ED-digoxin- 
conjugate for a limited number of antibody sites. The digoxin 
concentration in the sample is linearly proportional to the amount of 
^-galactosidase formed. The amount of active ^-galactosidase formed 
by recombination of EA and ED digoxin components is determined by 
measuring the rate of chlorophenol red-)9-D-galactopyranoside 
hydrolysis at 570 nm. This is the substrate for the 5 minute test 
and 0-nitrophenyl-/9-D galactopyranoside substrate for the 15 minute 
digoxin test which is measured at 420 nm.
5.3.5. CEDIA Assay Procedure:
The parameter listing for the assay is illustrated in (Table 18) . 
The protocol of Henderson et al. which performs a "calibration curve 
fit" and calculation of results could not be used as the old "Dens" 
software in the Cobas Bio was not sophisticated enough. Rate of 
absorbance was used instead for manual calculation by changing the 
"Type of Analysis 7.3" to "3" and "Printout Mode 5" to "2".
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A volume of 100/j1 of digoxin calibrators, controls and patients' 
samples were placed in cups in the carousel. The main cavity of the 
reagent boat was filled with 4 ml of enzyme-acceptor and 2.5 ml of 
enzyme-donor was placed in the "start" reagent compartment. The 
reagent boat and sample carousel were loaded and the run started. 
The appropriate volumes of sample and enzyme-acceptor reagents were 
added to each cuvette and mixed for 5 seconds by centrifugation. 
This was followed by a 10 second incubation period during which time 
an auxiliary reading was taken at 420 nm. The auxiliary reading is 
used to give an account of reagent integrity, but is not involved in 
the calculation of absorbance rate changes. After the incubation 
time enzyme-donor was added and mixed for 5 seconds followed by a 700 
second incubation time. A total of 21 absorbance readings were then 
taken at 10 second intervals. The instrument compared each 
absorbance and performed a linear regression. The rate of change of 
absorbance was calculated by subtracting the lower from the higher 
absorbance rate.
1 1 5
F i g u r e
I
The lac operon consists of the operator, promotor, Z, Y 
and A genes. The Z gene encodes galactosldase; mutant Z 
genes encode enzyme-acceptors (EAs) and enzyme-donors 
(EDs). Both EAs and EDs are enzymatically inactive but, 
when mixed, spontaneously associate to form enzymatically 
active /¡-galactosldase.
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Ananalyte (0) is attached to an ED such that the 
analyte-ED conjugate spontaneously recombines vith EA to 
yield active /J-gslactosidase (1). The addition of 
analyte-specific antibody inhibits spontaneous enzyme 
assembly (2). Analyte (0) In patients' serum modulates 
enzyme assembly so that the signal generated by substrate 
turnover is directly proportional to analyte 
concentration.
'  +  CD
f  + C9
f  + C3
f  + 0
F i g u r e  1 2 :  P r i n c i p l e  o f  CED IA  I m m u n o a s s a y s .
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5 . 4 .  SAMPLE COLLECTION:
Patient samples were taken into vacutainers with no anticoagulant. 
Samples for therapeutic monitoring of digoxin were drawn from 
patients at least eighteen hours after oral administration in order 
to allow time to complete the distribution phase. Samples for 
maintenance dose estimations were drawn from patients with steady 
state concentrations. The term steady state refers to a state of 
equilibrium between the quantity of drug being administered and the 
quantity eliminated.
(a) Serum was collected from 52 patients for digoxin estimation. 
Each sample was divided into three equal volumes and stored at 
-20°C in plastic tubes. One aliquot was sent to the external 
laboratory for analysis by RIA and the remaining two analysed by 
the CEDIA and EMIT methods.
(b) The salivary study involved the simultaneous collection of 20 
paired salivary and serum samples. They were stored at -20°C.
(c) In order to investigate cross-reactivity by DLIFs in both 
assays, samples were collected as follows:
Simultaneous serum and saliva samples were taken from 20 adult 
patients with known renal and hepatic dysfunction. Serum 
creatinine and liver function tests were performed by routine 
laboratory analysis. Serum and saliva samples were also 
collected simultaneously from 12 third trimester pregnant women 
and sera only from 8 neonates varying in age from 1 to 7 days.
(d) To investigate if a correlation exists between the degree of 
liver dysfunction and serum DLIF concentrations, samples were 
collected from 1 adult patient at 2 day intervals over an 8 day
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period. The samples were stored at -20°C.
(e) Serum and plasma was collected from patients not on digoxin. 
These patients showed normal renal, l iv e r  and cardiac function 
as assessed by measuring urea, electrolytes, creatinine, 
bilirubin, transaminases, alkaline phosphatase, gamma glutamyl 
transferase, creatine kinase and lactate  dehydrogenase. Pools 
were prepared, aliquoted and stored at -20°C for use in recovery 
and s t a b il i t y  studies. The serum pool was also used as a 
diluent to investigate possible interference due to haemoglobin, 
lipids and bilirubin.
(f) Serum samples containing high concentrations of (a) bilirubin,  
and (b) triglyceride were pooled, aliquoted and stored at -20°C.
(f) A number of blood samples were collected from patients not on
digoxin with normal renal, cardiac and liv e r  function tests.  
These bloods were stored at -20°C for 2 hours approximately. 
The resulting haemolysed samples were centrifuged, thawed and 
the serum was pooled and stored at -20°C for subsequent 
haemoglobin interference studies. A further 8 samples were
collected from patients on digoxin. After centrifugation 1.0 ml 
approx. of non-haemolysed serum was removed and stored at -20°C. 
The remaining serum from each sample was haemolysed as described 
above, analysed for haemoglobin using the Coulter Counter and 
stored at -20°C.
(h) A number of digoxin-free sera and saliva  samples were collected
from patients with normal renal function and cardiac function 
tests. Separate saliva and serum pools were prepared and stored 
at -20°C for use as a diluent in the salivary digoxin study.
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C h a p t e r  6
ANALYTICAL STUDIES
6.1 SERUM DIGOXIN MEASUREMENT:
6.1.1. Imprecision Studies:
These show the agreement between replicate measurements of serum 
digoxin concentration using the EMIT and CEDIA methods.
(a) Within Run Imprecision:
This was assessed using 20 replicate analyses of the three 
Gilford controls.
(b) Total Imprecision:
This was assessed over 20 days using daily measurements of the 
three Gilford controls.
6.1.2. Sensitivity Study:
This is a measure of the ability of the CEDIA and EMIT methods to 
detect low concentrations of digoxin. It has no numerical value but 
is expressed by the term "detection limit". This is the smallest 
single result with a state of probability (commonly 95%) which can be 
distinguished from the zero calibrator. The sensitivity of all the 
methods was determined by assaying 15 replicates of the zero 
calibrator. The absorbance readings obtained by each method were 
used to determine the digoxin concentrations from which the mean + 2 
SD was calculated. This defines the sensitivity of the method.
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6 . 1 . 3 .  Analytical Range:
This is the concentration range over which no modification is 
required in the CEDIA or EMIT methods and is determined by a 
"1inearity experiment".
(a) A digoxin solution of 10 /xmol/L was prepared by dissolving 
7.8125 /¿g of digoxin in 25 mis of pyridine. This was then 
diluted to one litre with a solution made up as follows:
(i) 6 tablets of phosphate buffered saline, pH 7.3, dissolved
in distilled water.
(ii) 4.00 ml of human serum albumin 20% (albuminar-20) giving 
an albumin concentration of JO g/1.
(iii) 20 mmol/L of sodium azide as preservative prepared by 
adding 1.3 g to the solution.
(b) A digoxin-free diluent solution was prepared similarly to the 
above solution. A number of dilutions were then prepared 
yielding digoxin concentrations from 0.5 - 10 nmol/L (see Table
19).
(c) A digoxin-free diluent solution for saliva was prepared 
similarly to that for (a) except that 400 ml of albuminar-20 was 
added resulting in an albumin concentration of 80 g/1 along with 
6 tablets of phosphate buffered saline, pH 7.3 made up to 1 
litre using distilled water.
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T a b l e  1 9 :  D i l u t i o n  p r o t o c o l  f o r  p r e p a r a t i o n  o f  s o l u t i o n s  t o  a s s e s s
a n a l y t i c a l  r a n g e .
Digoxin Standard 
10 (/¿mol/L)
Diluent Digoxin Cone. 
(nmol/L)
/il Ml
50 950 0.5
100 900 1.0
150 850 1.5
200 800 2.0
250 750 2.5
300 700 3.0
400 600 4.0
500 500 5.0
550 450 5.5
600 400 6.0
700 300 7.0
800 200 8.0
900 100 9.0
1000 0 10.0
The diluent used was that described in Section 6.1.3 (b).
%
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6 . 1 . 4 .  Recovery Studies:
These studies show the agreement between the best estimate of the 
serum digoxin concentration and its true value using the CEDIA and 
EMIT methods. Accuracy was assessed by spiking the pooled 
digoxin-free serum with the 10 /imol/L digoxin standard. This gave 
various concentrations covering the analytical range. Spiked 
solutions were prepared to a volume of 1 ml as in Table 20.
1 2 3
assessment of accuracy
T a b l e  2 0 :  D i l u t i o n  p r o t o c o l  f o r  d i g o x l n  s o l u t i o n s  u s e d  i n  t h e
Digoxin Standard 
conc. (10 /¿mol/L)
Digoxin-free
serum
Digoxin conc. 
(nmol/L)
Ml Ml
50 950 0.5
100 900 1.0
200 800 2.0
300 700 3.0
400 600 4.0
500 500 5.0
Each of these solutions was measured 10 times and the mean 
concentration of each was used to calculate the percentage recovery.
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6 . 1 . 5 .  Calibration Curve Stability:
A calibration curve was established for the EMIT and stored in the 
instrument using the "DENS" option. The stability of the working 
reagents as reflected by the stability of the curves was tested at 2 
day intervals up to 18 days by measuring the calibrators as samples 
along with 3 control sera. A calibration curve for the CEDIA was 
plotted using absorbance readings obtained at 420 nm versus 
concentration. The stability study
procedure was similar to the EMIT except absorbance values were taken 
and the concentration read from the manually plotted graph.
6.1.6. I n t e r f e r e n c e  S t u d i e s :
(a) DLIFs:
The samples collected from the various groups of patients (5.4) 
were used to investigate cross-reactivity in the kits.
(b) Bilirubin:
The pooled sample when analysed gave a bilirubin concentration 
of 312 /¿mol/1.
These pools were mixed with a normal digoxin-free pool to give 
different levels of the potential interferent. Different 
digoxin concentrations were then added as illustrated in Tables 
21-23.
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ference studies at digoxin concentrations of 2 nmol/L.
T a b l e  2 1 :  D i l u t i o n  p r o t o c o l  f o r  b i l i r u b i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Pooled Bilirubin Digoxin-free 
conc. (312 pmol/L) serum
Digoxin Std. 
(40 ¿imol/L)
Bilirubin  
conc.
Ml Ml Ml (/imol/L)
900 50 50 280.8
850 100 50 265.2
800 150 50 249.6
750 200 50 234.0
700 250 50 218.4
650 300 50 202.8
600 350 50 187.2
550 400 50 171.6
500 450 50 156.0
450 500 50 140.4
425 525 50 132.6
400 550 50 124.8
350 600 50 109.2
250 700 50 78.0
200 750 50 62.4
175 775 50 54.6
150 800 50 46.8
100 850 50 31.2
50 900 50 15.6
The 40 /¿rnol/L digoxin standard was prepared using 31.25 ¿tg of digoxin 
and following the procedure for the 10 /¿mol/L standard [6.1.3 (a)].
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ference studies at digoxin concentrations of 3 nmol/L.
T a b l e  2 2 :  D i l u t i o n  p r o t o c o l  f o r  b i l i r u b i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Pooled Bilirubin Digoxin-free 
conc. (312 pmol/L) serum
Digoxin Std. 
(40 /imol/L)
Bilirubin  
conc.
Ml Ml Ml (/jmol/L)
900 25 75 280.8
850 75 75 265.2
800 125 75 249.6
750 175 75 234.0
700 225 75 218.4
650 275 75 202.8
600 325 75 187.2
550 375 75 171.6
500 425 75 156.0
450 475 75 140.4
425 500 75 132.6
400 525 75 124.8
350 575 75 109.2
250 675 75 78.0
200 725 75 62.4
175 750 75 54.6
150 775 75 46.8
100 825 75 31.2
50 875 75 15.6
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ference studies at digoxin concentrations of 4 nmol/L.
T a b l e  2 3 :  D i l u t i o n  p r o t o c o l  f o r  b i l i r u b i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Fooled Bilirubin Digoxin-free 
conc. (312 /tmol/L) serum
Digoxin Std. 
(40 /imol/L)
Bilirubin  
conc.
Ml Ml Ml (/imol/L)
900 _ 100 280.8
850 50 100 265.2
800 100 100 249.6
750 150 100 234.0
700 200 100 218.4
650 250 100 202.8
600 300 100 187.2
550 350 100 171.6
500 400 100 156.0
450 450 100 140.4
425 475 100 132.6
400 500 100 124.8
350 550 100 109.2
250 650 100 78.0
200 700 100 62.4
175 725 100 54.6
150 750 100 46.8
100 800 100 31.2
50 850 100 15.6
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( c )  Lipids:
The pooled sample when analysed resulted in a serum triglyceride  
concentration of 18.94 mmol/L and a serum cholesterol concentration 
of 7.49 mmol/L. The procedures used in this study are shown in 
Tables 24 - 26.
Table 24: Dilution protocol for lip id  solutions used in inter­
ference studies at digoxin concentrations of 2 nmol/L.
Pooled Serum Digoxin-free Digoxin Trig. Choi.
T r ig .18.94 mmol/L Serum Std. Cone. Cone.
Choi.7.49 mmol/L (40/xmol/L)
Ml Ml Ml (mmol/L) (mmol/L)
900 50 50 17.05 6.74
850 100 50 16.10 6.37
800 150 50 15.15 6.00
750 200 50 14.21 5.62
700 250 50 13.26 5.24
650 300 50 12.31 4.87
600 350 50 11.36 4.49
550 400 50 10.42 4.12
500 450 50 9.47 3.75
450 500 50 8.52 3.37
400 550 50 7.58 3.00
350 600 50 6.63 2.25
250 700 50 4.74 1.87
150 800 50 2.84 1.12
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ference studies at digoxin concentrations of 3 nmol/L.
T a b l e  2 5 :  D i l u t i o n  p r o t o c o l  f o r  l i p i d  s o l u t i o n s  u s e d  i n  i n t e r ­
Fooled Serum Digoxin-free Digoxin 
T rig.18.94 mmol/L Serum Std. 
Choi. 7.49 mmol/L (40/imol/L)
Trig.
Cone.
Choi. 
Cone.
Ml Ml /il (mmol/L) (mmol/L)
900 25 75 17.05 6.74
850 75 75 16.10 6.37
800 125 75 15.15 6.00
750 175 75 14.21 5.62
700 225 75 13.26 5.24
650 275 75 12.31 4.87
600 325 75 11.36 4.49
550 375 75 10.42 4.12
500 425 75 9.47 3.75
450 475 75 8.52 3.37
400 525 75 7.58 3.00
350 575 75 6.63 2.25
250 625 75 4.74 1.87
150 675 75 2.84 1.12
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ference studies at digoxin concentrations of 4 nmol/L.
T a b l e  2 6 :  D i l u t i o n  p r o t o c o l  f o r  l i p i d  s o l u t i o n s  u s e d  i n  i n t e r ­
Fooled Serum 
T rig .18.94 mmol/L 
Choi.7.49 mmol/L
Digoxin-free
Serum
Digoxin 
Std. 
(40/imol/L)
Trig. 
Cone.
Choi. 
Cone.
Ml Ml Ml (mmol/L) (mmol/L)
900 25 75 17.05 6.74
850 75 75 16.10 6.37
800 125 75 15.15 6.00
750 175 75 14.21 5.62
700 225 75 13.26 5.24
650 275 75 12.31 4.87
600 325 75 11.36 4.49
550 375 75 10.42 4.12
500 425 75 9.47 3.75
450 475 75 8.52 3.37
400 525 75 7.58 3.00
350 575 75 6.63 2.25
250 625 75 4.74 1.87
150 675 75 2.84 1.12
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Serum samples from patients A, B and C with increased lipid 
concentration as determined by routine analysis were also studied for 
interference studies. The 5.12 nmol/L digoxin standard was used.
Table 27: Dilution protocol for lip id  solutions used in inter­
ference studies for Patients A, B and C.
Patient Digoxin Std. 
(5.12 nmol/L)
Digoxin 
Cone. 
(nmol/L)
Trig. 
Cone. 
(mmol/L)
Choi. 
Cone. 
(mmol/L)
A:
Trig. 11.6  
Choi. 12.8
mmol/L
mmol/L
Ml Ml
100 300 1.28 2.9 3.2
100 200 3.41 3.87 4.27
200 200 2.56 5.8 6.4
200 100 1.706 7.74 8.54
B:
Trig. 14.0 
Choi. 18.2
mmol/L
mmol/L
Ml Ml
100 300 1.28 3.5 4.55
100 200 3.41 4.66 6.06
200 200 2.56 7.0 9.1
200 100 1.706 9.31 12.12
C:
Trig. 18.2 
Choi. 10.5
mmol/L
mmol/L
Ml Ml
100 300 1.28 4.6 2.62
100 200 3.41 6.07 3.50
200 200 2.56 9.1 5.25
200 100 1.706 12.13 7.0
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(d) H aem oglob in  :
The pooled haemolysed samples, when analysed gave a haemoglobin 
concentration of 700 mg/dl. The dilution protocol used in the 
haemoglobin study are shown in Tables 28 - 30.
Table 28: Dilution protocol for haemoglobin solutions used in Inter­
ference studies at digoxin concentrations of 2.0 nmol/L.
Pooled Hb 
(Cone. 700mg/dl)
Digoxin-free 
Serum
Digoxin
Std.
(40/imol/L)
Hb Conc. 
(mg/dl)
Ml Ml Ml
750 200 50 525
650 300 50 455
550 400 50 385
450 500 50 315
400 550 50 280
380 570 50 266
350 600 50 245
250 700 50 175
150 800 50 105
130 820 50 91
115 835 50 80.5
100 850 50 70.0
90 860 50 63.0
80 870 50 56.0
1 3 3
ference studies at digoxin concentrations of 3.0 nmol/L.
T a b l e  2 9 :  D i l u t i o n  p r o t o c o l  f o r  h a e m o g l o b i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Pooled 
(Cone.
Hb Digoxin-free 
700mg/dl) Serum
Digoxin
Std.
(40/imol/L)
Hb Cone. 
(mg/dl)
Ml Ml /il
750 175 75 525
650 275 75 455
550 375 75 385
450 475 75 315
400 525 75 280
380 545 75 266
350 575 75 245
250 675 75 175
150 775 75 105
130 795 75 91
115 810 75 80.5
100 825 75 70.0
90 835 75 63.0
80 845 75 56.0
rable 30 Dilution protocol for haemoglobin solutions used in inter­
ference studies at digoxin concentrations of 4.0 nmol/L.
Pooled Hb Digoxin-free Digoxin Hb Cone.
(Cone. 700mg/dl) Serum Std.
(40/imol/L)
(mg/dl)
Ml Ml Ml
750 150 100 525
650 250 100 455
550 350 100 385
450 450 100 315
400 500 100 280
380 520 100 266
350 550 100 245
250 650 100 175
150 750 100 105
130 770 100 91
115 785 100 80.5
100 800 100 70.0
90 810 100 63.0
80 820 100 56.0
1 3 4
( e )  Protein:
This was prepared by spiking 1.0 ml of phosphate buffered saline, pH
7.3 with 1.0 ml of albuminar-20 (human serum albumin 20% w/v) which, 
when analysed resulted in a serum protein concentration of 122 g/L. 
The phosphate buffered saline, pH 7.3 used in this study was prepared 
by dissolving 10 phosphate tablets in one litre of distilled water. 
The dilution protocol used in the study is shown in Tables 31-33.
rable 31: Dilution protocol for protein solutions used in inter-
ference studies at digoxin concentrations of 2 nmol/L.
Phosphate Phosphate Digoxin Protein Digoxin
Buffered Buffer, Std. Cone. Cone.
Protein
(122 g/L) pH 7.3. (40/zmol/L) (g/L) (nmol/L)
fj.1 ni Ml
915 35 50 111.63 2
900 50 50 109.8 2
850 100 50 103.7 2
800 150 50 97.6 2
750 200 50 91.5 2
700 250 50 85.4 2
650 300 50 79.3 2
600 350 50 73.2 2
550 400 50 67.1 2
500 450 50 61.0 2
450 500 50 54.9 2
400 550 50 48.8 2
350 600 50 42.7 2
250 700 50 30.5 2
150 800 50 18.3 2
100 850 50 12.2 2
50 900 50 6.1 2
1 3 5
ference studies at digoxin concentrations of 3 nmol/L.
T a b l e  3 2 :  D i l u t i o n  p r o t o c o l  f o r  p r o t e i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Phosphate 
Buffered 
Protein 
(122 g/L)
Phosphate
Buffer,
pH 7.3.
Digoxin
Std.
(40/imol/L)
Protein 
Cone.
(g /L )
Digoxin 
Cone.
(nmol/L)
Ml Ml Ml
915 10 75 111.63 3
900 25 75 109.8 3
850 75 75 103.7 3
800 125 75 97.6 3
750 175 75 91.5 3
700 225 75 85.4 3
650 275 75 79.3 3
600 325 75 73.2 3
550 375 75 67.1 3
500 425 75 61.0 3
450 475 75 54.9 3
400 525 75 48.8 3
350 575 75 42.7 3
250 675 75 30.5 3
150 775 75 18.3 3
100 825 75 12.2 3
50 875 75 6 . 1 3
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ference studies at digoxin concentrations of 4 nmol/L.
T a b l e  3 3 :  D i l u t i o n  p r o t o c o l  f o r  p r o t e i n  s o l u t i o n s  u s e d  i n  i n t e r ­
Phosphate 
Buffered 
Protein 
(122 g/L)
Phosphate
Buffer,
pH 7.3.
Digoxin 
Std.
(40/imol/L)
Protein 
Cone.
(g/L)
Digoxin 
Cone.
(nmol/L)
Ml Ml Ml
900 _ 100 109.8 4
850 50 100 103.7 4
800 100 100 97.6 4
750 150 100 91.5 4
700 200 100 85.4 4
650 250 100 79.3 4
600 300 100 73.2 4
550 350 100 67.1 4
500 400 100 61.0 4
450 450 100 54.9 4
400 500 100 48.8 4
350 550 100 42.7 4
250 650 100 30.5 4
150 750 100 18.3 4
100 800 100 12.2 4
50 850 100 6.1 4
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6.1.7. Suitability and Stability of Digoxin in Serum and Plasma:
This study was performed to ascertain:
(a) The suitability of the use of serum or plasma sample for digoxin 
analysis using the CEDIA and EMIT methods.
(b) The stability of digoxin in serum or plasma at various 
temperatures since samples were stored for use in this project. 
Pooled digoxin-free serum and plasma was spiked with digoxin to 
give a final concentration of 1.0 nmol/L (25 ¿il of 40 /tmol/L 
stock standard and 950 fil of pooled serum) . 10 ml volumes were 
prepared aliquoted and stored at 2-8°C, room temperature, and 
-20°C. Replicate analyses were performed on these samples at 
intervals up to 18 days.
A further study was performed using two serum aliquots from 5 
patients on digoxin. One of the aliquots was added to a heparinized 
vacutainer and the other stored in a tube containing no 
anticoagulant. Heparinised and serum samples were taken
simultaneously from six of the eleven patients.
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6 . 2  SALIVARY DIGOXIN MEASUREMENT:
6.2.1. EMIT Column Digoxin Assay:
Reagent preparation extraction and assay procedures used were similar 
to those for serum digoxin (Section 5.2). The parameter listing is 
shown in Table 34.
6.2.2. CEDIA Digoxin Assay:
(a) Reagent Preparation:
The same procedure as for serum digoxin was used.
(b) Assay Procedure:
The sample volume of 25 pi used in the serum digoxin protocol 
was increased to 50 /il for salivary digoxin estimations. Sample 
preparation involved the addition of 0.1 ml of digoxin-free 
serum pool (6.1.3.c) to 0.1 ml of saliva. The parameter 
listing is shown in Table 34.
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CEDIA digoxin assay and EMIT assay.
T a b l e  3 4 :  C o b a s  B i o  p a r a m e t e r  l i s t i n g  f o r  s a l i v a r y  d i g o x i n  u s i n g  t h e
CEDIA EMIT
a Reaction direction/Test name 11;44;49;47 (+ Digoxin)
1 Units 14 (nmol/L) 14 (nmol/L)
2 Calculation factor 3333.3 3700
3 Standard 1 0.0 0.0
3 Standard 2 2.56 0.64
3 Standard 3 5.12 1.28
3 Standard 4 2.56
3 Standard 5 3.84
3 Standard 6 5.12
6 Limit 0 0
7 Temperature 37°C 37°C
8 Type of Analysis 3 7.3
9 Wavelength (nm) 420 340
10 Sample volume /il 50 30
11 Diluent volume /¿I 10 60
12 Reagent volume /¿I 120 115
13 Incubation time sec. 10 100
14 Start reagent volume /il 75 45
15 Time of first reading sec. 700 5
16 Time interval sec. 10 10
17 Number of readings sec. 21 25
18 Blanking mode 0 0
19 Printout mode 2 0/1
*
1 4 0
6.2.3. Salivary Calibration Curve:
(a) EMIT Assay:
The standards used for the calibration curve are shown in Table 
35.
(b) CEDIA Assay:
0.1 ml of digoxin-free pooled saliva was added to 0.1 ml of the 
0.0, 2.56 and 5.12 nmol/L digoxin standards.
6.2.4. Sensitivity Studies:
The zero calibrator (Table 35) was used for the EMIT method. For the 
CEDIA assay an equal volume of zero calibrator (serum) and
digoxin-free saliva were mixed. The sensitivity was determined by 
assaying 10 replicates of the zero calibrator solution and
calculating the concentration of digoxin which gave an identical 
response to that of 2.5 standard deviations above the zero
calibrator.
6.2.5. Analytical Range:
A number of standards ranging from 0.0 to 10 nmol/L were used in this 
study (Table 35) . The procedures are similar to the sensitivity
studies (6.2.4.).
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Table 35; Dilution protocol for preparation of solutions to assess 
analytical range for salivary digoxin.
Digoxin Standard 
(10 /¿mol/L)
Ml
Digoxin-Free 
Pooled Saliva
Ml
Digoxin Cone. 
(nmol/L)
0 1000 0.0
50 950 0.5
100 900 1.0
200 800 2.0
300 700 3.0
400 600 4.0
500 500 5.0
600 400 6.0
700 300 7.0
800 200 8.0
900 100 9.0
1000 - 10.0
The preparation of the digoxin standard solution is described in 
Section 6.1.3. (a).
%
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6.2.6. Imprecision Studies:
Using the three Gilford controls reproducibility was determined by 
mixing an equal volume of pooled digoxin-free saliva and controls for 
both methods.
(a) Within Run Imprecision:
This was determined using 20 replicate analysis of the three 
Gilford controls.
(b) Total Imprecision:
This was assessed by analysing the three Gilford controls at 
daily intervals over 20 days.
6.2.7. Recovery Studies:
Accuracy was assessed by spiking digoxin-free saliva with 10 jumol/L 
digoxin standard covering the analytical range of the method. The 
digoxin standard was prepared as in Section 6.1.3. (a) (Table 36).
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recovery studies.
T a b l e  3 6 :  P r o t o c o l  f o r  t h e  p r e p a r a t i o n  o f  d i g o x i n  s o l u t i o n s  u s e d  i n
Digoxin Standard 
(10 /¿mol/L)
/il
Digoxin-Free 
Pooled Saliva
/il
Digoxin Cone. 
(nmol/L)
50 950 0.5
100 900 1.0
200 800 2.0
300 700 3.0
400 600 4.0
500 500 5.0
Each solution was assayed 5 times and the mean concentration was used 
to determine percentage recovery.
1 4 4
6.2.8. Interference Studies:
A study was performed to investigate the presence of DLIFs in saliva 
from patients with renal failure, liver dysfunction and in third 
trimester pregnant women. None of these patients were receiving 
digoxin therapy.
6.2.9. Assay of Free Serum Digoxin:
Equilibrium dialysis was used to determine free serum digoxin. 
Dialysis was carried out in small Type A Teflon cells (Figure 13) , 
designed for the analysis of free thyroxine hormones in serum [107]. 
The procedure used in free thyroxine estimation involved the 
pipetting of 5 ml of dialysis buffer into the main chamber of the 
cell and placing a Visking dialysis membrane across the top secured 
by an annular clamping ring. A 200 /¿I volume of test serum was 
pipetted into the small chamber above the membrane. The cell was 
stoppered and placed in a water bath for 18 hours at 37°C.
The procedure was reversed for digoxin estimation, with 5 ml of serum 
being placed in the main chamber. 500 1 of phosphate buffered
saline, pH 7.3, was pipetted above the membrane in the small chamber. 
The cell was then stoppered and placed in a water bath for 16 hours 
at 37°C with periodic shaking. The dialysate was removed from the 
small chamber above the membrane. Both dialysate and serum were 
assayed for digoxin concentration using both the CEDIA salivary and 
serum digoxin methods, respectively.
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This study was performed on eight patients with normal renal, liver 
and cardiac function tests.
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Figure 13:
Stopper
Type A Teflon cell.
Equilibrium dialysis was used to determine free 
serum digoxin concentrations.
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Chapter 7
ASSAY PERFORMANCE
7.1. IMPRECISION STUDIES:
The within batch and total imprecision performances of the EMIT and 
CEDIA assays follow.
7.1.1. EMIT Column Digoxin Assay:
Gilford Level I:
Within Batch
Mean = 1.85 nmol/L 
SD = 0.05 nmol/L 
CV = 2.7%
Total
Mean = 1.92 nmol/L 
SD = 0.07 nmol/L 
CV - 3.6%
Gilford Level II: Mean = 3 . 0  nmol/L
SD = 0.09 nmol/L 
CV = 3.0%
Mean =2.91 nmol/L 
SD = 0.13 nmol/L 
CV = 4.5%
Gilford Level III: Mean = 4 . 4  nmol/L
SD = 0.21 nmol/L 
CV = 4.8%
Mean =4.64 nmol/1 
SD = 0.27 nmol/L 
CV = 5.8%
Number of estimates = 20.
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7 . 1 . 2 .  CEDIA Digoxin Assay:
Gilford Level I:
Within Batch
Mean = 1.80 nmol/L 
SD = 0.53 nmol/L 
CV - 2.94%
Mean - 1.98 nmol/L 
SD - 0.74 nmol/L 
CV = 3.75%
T o t a l
Gilford Level II:
Gilford Level III:
Mean = 3.06 nmol/L 
SD = 0,10 nmol/1 
CV = 3.3%
Mean =4.32 nmol/L 
SD = 0.22 nmol/L 
CV = 5.1%
Mean =3.15 nmol/L 
SD = 0.145 nmol/L 
CV = 4.6%
Mean =4.58 nmol/L 
SD = 0.28 nmol/L 
CV = 6.15
Number of estimates = 20.
These results compare well with those of the EMIT. The mean 
concentrations observed compare well with the target values quoted 
for the quality control materials (Section 5.1.2.). In general, the 
two methods are considered reproducible enough for routine use.
1 4 9
7.2. SENSITIVITY:
Values of 15 replicates of the zero calibrator.
MEAN
SD
Detection Limit (Mean + 2 SD)
EMIT 
Digoxin Cone. 
(nmol/L)
0.2
0.03
0.275
CEDIA 
Digoxin Cone. 
(nmol/L) 
0.22 
0.032 
0.30
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7.3. ANALYTICAL RANGE:
EMIT CEDIA
Range 0.275 - 6.0 nmol/L 0.3 - 5.12 nmol/1
Response Logarithmic Linear
Figures 14-15 show the responses of both methods to digoxin 
concentrations ranging from 0.64 to 5.12 nmol/1. A rate change of 
approximately 28 mA was noted for each 1.28 nmol/L of digoxin for the 
CEDIA method.
7.4. RECOVERY:
The accuracy of the recovery of digoxin from samples spiked to 
concentrations covering the analytical range was assessed. Table 36 
shows the mean percentage recovery for each method at concentrations 
over the analytical range. The figures in parenthesis are 
coefficients of variations for the ten estimates.
Table 36: The mean percentage recoveries for both methods:
Digoxin conc. % RECOVERY
(nmol/1) EMIT CEDIA
0.64 96 (5.9) 97 (5.8)
1.28 103 (4.3) 98 (5.7)
2.56 99 (3.5) 101 (4.6)
3.84 102 (3.8) 97 (4.4)
5.12 98 (4.7) 102 (5.5)
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Figure 14: Calibration curve for EMIT immunoassay.
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7.5 CALIBRATION CURVE STABILITY:
The stability of the calibration curves is shown in Figures 16 and 
17. The calibration curves for the EMIT and CEDIA assays were stable 
for the first 12 days followed by decreasing digoxin concentration 
values.
7.6. INTERFERENCE STUDIES:
7.6.1. DLIF Cross-Reactivity:
Digoxin-free serum from patients in renal failure, liver disease, 
third trimester pregnancy and neonates was tested for DLIF 
interference using the CEDIA and EMIT methods. These groups were 
selected since they are widely reported as having significant DLIF 
concentrations that interfere with most digoxin immunoassays. DLIF 
concentration was measured as "apparent digoxin" in each group.
(a) Renal Failure:
Table 37: DLIF determined as "apparent digoxin" in renal failure.
Creatinine 
(/X mol/L)
"Apparent Digoxin" 
(/imol/L)
CEDIA EMIT
Mean 665 0.74 0.024
SD 382 0.24 0.06
Range (min-max) 134-1609 0.0-1.05 0.0-0.2
154
Figure 18 shows DLIF cross-reactivity as "apparent digoxin" in both 
assays.
In renal failure the EMIT method detected no DLIF in 16 samples and 
in the other 4 samples DLIF concentrations did not exceed 0.2 runol/L. 
The EMIT greatly reduced or eliminated DLIF in the patients studied. 
In contrast, the CEDI A had only one sample where DLIF was not 
detected with 12 samples within the range 0.8 to 1.05 nmol/L. The 
remaining 7 samples had concentrations between 0.4 and 0.8 nmol/L. In 
renal disease DLIFs showed a significant interference with the CEDIA 
method.
155
( b )  L i v e r  D i s e a s e :
T a b l e  3 8 :  D L IF  d e t e r m i n e d  a s  " a p p a r e n t  d i g o x i n "  i n  l i v e r  d i s e a s e .
Bilirubin
(/imol/L)
"Apparent Digoxin" 
(nmol/L)
CEDIA EMIT
Mean 70 0.19 0.06
SD 26 0.13 0.09
Range (min-max) 18-146 0.0-0.4 0.0-0.23
Figure 19 shows DLIF interference as "apparent digoxin" in both 
assays.
DLIFs were completely eliminated from 65% of the samples in the EMIT 
assay with 0.25 nmol/1 being the highest concentration achieved. 
Using the CEDIA method, DLIF concentrations were significantly lower 
than those reported for it in renal failure. The highest 
concentration recorded was 0.4 nmol/L with 5 samples showing no DLIF 
interference.
1 5 6
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Disoxin Concentracion (nmol/L)
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F i g u r e  1 8 :  C o n c e n t r a t i o n  o f  D L I F s  i n  R e n a l  F a i l u r e .
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Figure 19: Concentration of DLIFs in Liver Disease.
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(c) Third Trimester Pregnancy:
pregnancy.
T a b l e  3 9 :  D L IF  d e t e r m i n e d  a s  " a p p a r e n t  d i g o x i n "  i n  t h i r d  t r i m e s t e r
"Apparent Digoxin" Cone. 
(nmol/L)
CEDIA EMIT
Mean 0.613 0.06
SD 0.176 0.07
Range (min-max) 0.0-0.77 0.0-0.2
Figure 20 shows DLIF cross-reactivity as "apparent digoxin" in both
methods.
In pregnancy, 50% of samples had no DLIF detected using the EMIT and 
the remaining samples were within the range 0.05 to 0.2 nmol/L. The 
CEDIA method had 75% of the samples with DLIF concentrations ranging 
from 0.65 to 0.77 nmol/L with the remaining 3 samples giving 
concentrations from 0.28 - 0.38 nmol/L
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(d) Neonates :
T a b l e  4 0 :  D L IF  d e t e r m i n e d  a s  " a p p a r e n t  d i g o x i n ” i n  n e o n a t e s .
"Apparent Digoxin" Gone. 
(nmol/L)
CEDIA EMIT
Mean 0.7 0.12
SD 0.35 0.16
Range (min-max) 0.0-1.18 0.0-0.35
Figure 21 shows DLIF interference as "apparent digoxin" in both 
methods.
In neonates, over half the samples analysed had no DLIF present and 
the other samples had concentrations varying from 0.27 to 0.36 
nmol/L. In the CEDIA, only one sample had no DLIF detected with 75% 
of the samples having DLIF concentrations between 0.6 and 1.18 
nmol/L.
1 6 1
Figure 20: DLIF determined as "apparent dlgoxln" in third trimester
pregnancy.
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Figure 21: DLIF determined as "apparent dlgoxln" In neonates
o
6c
eo•r4utOu
u
c<v
V
coy
xooo
da
<aaCL<
• - Apparent dlgoxln concentration for each patient sample
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(e) Correlation between varying degrees of liver disease and serum
DLIF concentration from a single patient using the CEDIA assay:
Table 41: Shows the results.
Days Bilirubin Concentration
(/¿mol/1)
"Apparent Digoxin" 
(nmol/1)
0 106 0.40
2 94 0.43
4 63 0.58
6 41 0.62
8 21 0.60
It is apparent from the above table that no correlation exists. A 
reduction in serum bilirubin concentration results in increased 
"apparent digoxin concentration".
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7 . 6 . 2 .  Bilirubin:
Tables 42-44 show the effect of bilirubin on the measurement of 
digoxin by the EMIT and CEDIA assays. Digoxin recoveries using the 
EMIT were good showing similar values to those obtained for the 
accuracy studies. The results for the CEDIA show that with bilirubin 
at concentrations greater than 140.4 /¿mol/L no digoxin recovery was 
obtained for all concentrations measured. In fact, the absorbance 
readings obtained were less than those of the zero calibrator. 
Bilirubin concentrations of 54.6 /xmol/L or less showed good 
recoveries.
Table 42: The effect of pooled bilirubin serum on a digoxin
concentration of 2.0 nmol/L with the EMIT and CEDIA 
methods.
BILIRUBIN CONC. 
(fi mol/L)
DIGOXIN CONC. 
(nmol/1)
% RECOVERY 
EMIT CEDIA
280.8 2 102 0
265.2 2 104 0
249.6 2 95 0
234.0 2 103 0
218.4 2 97 0
202.8 2 94 0
187.2 2 96 0
171.6 2 102 0
156.0 2 95 0
140.4 2 105 0
132.6 2 101 9
124.8 2 99 17.8
109.2 2 95 28.1
78.0 2 97 49.0
62.4 2 99 69.1
54.6 2 101 84.3
46.8 2 98 90
31.2 2 105 96
15.6 2 103 97
1 6 4
concentration of 3.0 nmol/L with the EMIT and CEDIA 
methods.
T a b l e  4 3 :  T h e  e f f e c t  o f  p o o l e d  b i l i r u b i n  s e r u m  o n  a  d i g o x i n
BILIRUBIN CONC. 
(/¿mol/L)
DIGOXIN CONC. 
(nmol/1)
% RECOVERY 
EMIT CEDIA
280.8 3 96 0
265.2 3 102 0
249.6 3 104 0
234.0 3 95 0
218.4 3 97 0
202.8 3 94 0
187.2 3 101 0
171.6 3 103 0
156.0 3 100 0
140.4 3 98 0
132.6 3 103 5.1
124.8 3 96 12.6
109.2 3 97 32.1
78.0 3 99 52.0
62.4 3 101 72.0
54.6 3 96 84
46.8 3 103 96
31.2 3 104 97
15.6 3 102 95
1 6 5
concentration of 4.0nmol/L with the EMIT and CEDIA 
methods.
T a b l e  4 4 :  T h e  e f f e c t  o f  p o o l e d  b i l i r u b i n  s e r u m  o n  a  d i g o x i n
BILIRUBIN CONC. 
(/imol/L)
DIGOXIN CONC. 
(nmol/1)
% RECOVERY 
EMIT CEDIA
280.8 4 96 0
265.2 4 102 0
249.6 4 104 0
234.0 4 99 0
218.4 4 98 0
202.8 4 104 0
187.2 4 95 0
171.6 4 99 0
156.0 4 98 0
140.4 4 97 0
132.6 4 99 12.2
124.8 4 102 20.1
109.2 4 103 42.3
78.0 4 97 68.0
62.4 4 100 77.3
54.6 4 101 83.9
46.8 4 97 98.0
31.2 4 100 96.6
15.6 4 98 97.5
1 6 6
7 . 6 . 3 .  Lipids:
The results of these studies are presented in Tables 45-47. Lipids 
had no clinically significant effect on the determination of digoxin 
by the EMIT assay. In the CEDIA method, triglyceride concentrations 
greater than 15.15 mmol/L and cholesterol concentrations greater 
than 6.0 mmol/1 gave no digoxin recoveries and inhibition was such 
that absorbance readings less than the zero standard were obtained 
(Table 46) . Insignificant interference occured at triglyceride and 
cholesterol concentrations less than 9.47 mmol/L and 3.75 mmol/L, 
respectively. For the individual patient samples (Table 48) total 
recovery and inhibition occured at variable concentrations of 
triglyceride and cholesterol. For example, in patient C, 94% 
recovery occured at a triglyceride concentration of 6.17 mmol/L while 
patient A had 96% recovery at a concentration of only 3.87 mmol/L. A 
recovery of 90% was observed at a cholesterol concentration of 6.06 
mmol/L in patient B while only 63% was reported at 6.4 mmol/L for 
patient A.
*
1 6 7
concentration of 2.0 nmol/L using the EMIT and CEDIA 
methods.
T a b l e  4 5 :  T h e  e f f e c t  o f  p o o l e d  l i p a e m l c  s e r u m  o n  d i g o x i n
% RECOVERY
Trig. Cone. Choi. Cone. Digoxin Cone. EMIT CEDIA
(mmol/L) (mmol/L) (nmol/L)
17.05 6.74 2 102 0
16.1 6.37 2 105 0
15.15 6.00 2 97 0
14.21 5.62 2 98 40
13.26 5.24 2 100 57.6
12.31 4.87 2 102 69.8
11.36 4.49 2 97 81.2
10.42 4.12 2 104 88.4
9.47 3.75 2 96 90
8.52 3.37 2 99 95
7.58 3.00 2 105 96
6.63 2.25 2 97 104
4.74 1.87 2 101 101
2.84 1.12 2 103 100
1 6 8
concentration of 3.0 nmol/L using the EMIT and CEDIA 
methods.
T a b l e  4 6 :  T h e  e f f e c t  o f  p o o l e d  l i p a e m l c  s e r u m  o n  d i g o x i n
Trig. Cone. Choi. Cone. 
(mnmol/L) (mmol/L)
Digoxin Cone.
(nmol/ L )
%
EMIT
RECOVERY
CEDIA
17.05 6.74 3 96 0
16.1 6.37 3 98 0
15.15 6.00 3 101 0
14.21 5.62 3 95 34
13.26 5.24 3 97 54
12.31 4.87 3 102 66
11.36 4.49 3 96 79
10.42 4.12 3 104 88
9.47 3.75 3 103 93
8.52 3.37 3 99 96
7.58 3.00 3 104 97
6.63 2.25 3 98 96
4.75 1.87 3 101 102
2.84 1.12 3 97 101
Table 47: The effect of pooled lipaemic serum on digoxin
concentration of 4.0 nmol/L using the EMIT and CEDIA
methods.
% RECOVERY
Trig. Cone Choi. Cone. Digoxin Cone. EMIT CEDIA
(mmol/L) (mmol/L) (nmol/L)
17.05 6.74 4 94 0
16.1 6.37 4 102 0
15.15 6.00 4 97 0
14.21 5.62 4 98 37
13.26 5.24 4 95 49
12.31 4.87 4 99 63
11.36 4.49 4 102 77
10.42 4.12 4 97 86
9.47 3.75 4 104 92
8.52 3.37 4 101 99
7.58 3.00 4 99 95
6.63 2.25 4 103 102
4.74 1.87 4 104 95
2.84 1.12 4 97 103
1 6 9
%
Table 48: The Interference due to lip id s in patients A, B and C.
P a t i e n t
C h o i . C one . 
(mmol/L)
T r i g .  Cone.  
(mmol/L)
% R e c o v e ry  
EMIT CEDIA
A 3 .2 2 .9 0 98 97
4 .2 7 3 .8 7 97 96
6 . 4 5 .8 0 105 63
8 . 5 4 7 . 7 4 101 0
b 4 .5 5 3 . 5 99 97
6 .0 6 4 .6 6 104 90
9 . 1 7 .0 0 103 38
12.12 9 .3 2 96 0
C 2 .6 2 4 .5 5 94 98
3 .5 0 6 .1 7 100 94
5 .2 5 9 .1 0 104 68
7 . 0 12 .13 95 0
1 7 0
7 . 6 . 4 .  Haemoglobin:
These results are shown in Tables 49-51. The EMIT method had 
excellent recoveries with values ranging from 94% to 104%. For the 
CED1A, an average recovery of 94% was observed at a haemoglobin 
concentration of 70 mg/dl. However, there was no digoxin recovery 
with haemoglobin concentrations greater than 266 mg/dl. The 
absorbance values at these haemoglobin concentrations were less than 
those for the zero calibrator.
In Table 52, the CEDIA method had no absorbance readings recorded on 
the Cobas Bio printout for haemolysed sera with haemoglobin 
concentrations from 1.8 to 3.0 g/dl. They were "flagged" instead as 
"high absorbance". Using the EMIT method, the haemolysed samples for 
these 8 patients gave similar digoxin concentrations to those of the 
non-haemolysed samples.
1 7 1
concentration of 2 nmol/L by the EMIT and CEDIA method.
T a b l e  4 9 :  T h e  e f f e c t  o f  p o o l e d  h a e m o l y s e d  s e r u m  o n  a  d i g o x i n
Hb. Cone. 
(mg/dl)
Digoxin Cone. 
(nmol/L)
%
EMIT
RECOVERY
CEDIA
525 2 97 0
455 2 94 0
385 2 100 0
315 2 104 0
280 2 101 0
266 2 95 0
245 2 102 16
175 2 96 53
105 2 95 71
91 2 98 77
80.5 2 97 85
70.0 2 103 92
63.0 2 97 95
56.0 2 101 96
1 7 2
concentration of 3 nmol/L by the EMIT and CEDIA method.
T a b l e  5 0 :  T h e  e f f e c t  o f  p o o l e d  h a e m o l y s e d  s e r u m  o n  a  d i g o x l n
Hb. Cone 
(mg/dl)
Digoxin Cone. 
(nmol/L)
% RECOVERY 
EMIT CEDIA
525 3 102 0
455 3 96 0
385 3 95 0
315 3 97 0
280 3 94 0
266 3 99 0
245 3 101 12
175 3 97 43
105 3 102 68
91 3 103 80
80.5 3 100 87
70.0 3 96 94
63.0 3 95 99
56.0 3 98 101
Table 51: The effect of pooled haemolysed serum on a digoxin
concentration of 4 nmol/L by the EMIT and CEDIA method.
% RECOVERY
Hb. Cone Digoxin Cone. EMIT CEDIA
(mg/dl) (nmol/L)
525 4 95 0
455 4 98 0
385 4 104 0
315 4 99 0
280 4 102 0
266 4 101 0
245 4 96 18
175 4 97 57
105 4 99 70
91 4 104 79
80.5 4 102 84
70.0 4 101 96
63.0 4 99 100
56.0 4 100 98
1 7 3
and non-haemolysed serum from each sample where the 
dlgoxln concentration was determined.
T a b l e  5 2 :  S h o w s  r e s u l t s  o f  a  s t u d y  o n  8  p a t i e n t s  u s i n g  h a e m o l y s e d
Digoxin Cone. (nmol/L)
Hb Cone. Haemolysed Non-Haemolysed
Patient Cg/dl) CEDIA EMIT CEDIA EMIT
1 2.0 "High Abs" 1.6 1.5 1.7
2 2.5 "High Abs" 2.2 2.2 2.1
3 1.8 "High Abs" 2.4 2.6 2.4
4 2.4 "High Abs" 0.9 0.8 0.8
5 2.2 "High Abs" 1.3 1.1 1.0
6 1.9 "High Abs" 1.4 1.5 1.3
7 3.0 "High Abs" 1.5 1.3 1.4
8 2.8 "High Abs" 2.7 3.0 2.8
1 7 4
7 . 6 . 5 .  Protein:
Tables 53-55 show the effect of protein on digoxin estimation by the 
EMIT and CEDIA assays. In the EMIT method, excellent overall 
recovery was achieved. For the CEDIA method, very good recovery was 
attained between 42.7 and 79.3 g/1. Protein concentrations greater 
than this gave decreased digoxin recovery with 111.6 g/1 giving a 
mean of only 63%. Digoxin concentrations were over-estimated with 
protein concentrations of 30.5 g/1 or below.
Table 53: The effect of protein on a digoxin concentration of 2
nmol/L using the EMIT and CEDIA techniques.
Protein Cone.
(g/D
Digoxin Cone. 
(nmol/L)
%
EMIT
RECOVERY
CEDIA
111.6 2 96 57.5
109.8 2 98 62.5
103.7 2 101 70.0
97.6 2 95 77.5
91.5 2 104 80.0
85.4 2 97 85.0
79.3 2 102 97.5
73.2 2 103 95.0
67.1 2 99 102.5
61.0 2 96 105
54.9 2 97 100
48.9 2 103 92.5
42.7 2 101 105
30.5 2 100 128
18.3 2 97 140
12.3 2 96 152.5
6.1 2 101 235
*
1 7 5
nmol/L using the EMIT and CEDIA techniques.
T a b l e  5 4 :  T h e  e f f e c t  o f  p r o t e i n  o n  a  d i g o x i n  c o n c e n t r a t i o n  o f  3
Protein Cone. 
(g/D
Digoxin Cone. 
(nmol/L)
%
EMIT
RECOVERY
CEDIA
111.6 3 101 61.7
109.8 3 95 63.3
103.7 3 100 70
97.6 3 99 78.3
91.5 3 97 83.3
85.4 3 96 86.6
79.3 3 98 98
73.2 3 102 96.6
67.1 3 97 101.7
61.0 3 103 96.7
54.9 3 101 98.3
48.9 3 100 103.3
42.7 3 97 103
30.5 3 96 126
18.3 3 101 135
12.3 3 102 158.3
6.1 3 99 247
Table 55: The effect of protein on a digoxin concentration of 4
nmol/L using the EMIT and CEDIA techniques.
Protein Cone.
(g/D
Digoxin Cone. 
(nmol/L)
%
EMIT
RECOVERY
CEDIA
111.6 4 99 70
109.8 4 101 72.5
103.7 4 102 75
97.6 4 100 80
91.5 4 97 82.5
85.4 4 99 86.2
79.3 4 96 96
73.2 4 95 98.8
67.1 4 101 98.7
61.0 4 103 102.5
54.9 4 101 101
48.9 4 104 102.5
42.7 4 96 104
30.5 4 98 127
18.3 4 100 137.5
12.3 4 97 151
6.1 4 102 231
1 7 6
7 . 7 .  METHOD COMPARISONS:
Direct comparisons of the methods investigated using results from 52 
patients' samples are illustated in Figures 22 to 24. Data derived 
from linear regression is given as:
y (CEDIA) =0.91 (EMIT) + 0.17
y (CEDIA) =0.92 (RIA) + 0.16
y (EMIT) - 1.008 (RIA) + 0.009
The correlation between all the methods was found to be in good 
agreement within the range of the calibration curve.
1 7 7
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enzyme immunoassays.
F i g u r e  2 2 :  C o r r e l a t i o n  b e t w e e n  d i g o x l n  a s s a y e d  b y  E M IT a n d  CED IA
EMIT assav concentration (nmol/L)
Slope 0.91; Intercept (nmol/L) 0.17; Mean (nrool/L);
EMIT 1.53; CEDIA 1.66; Correlation Coef£icient 0.985; 
y = 0.91x + 0.17; n = 52.
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23: Correlation between digoxln assayed by RIA and CEDIA
methods.
RIA Assay concentration (nmol/L)
Slope 0.92; Intercept (nmol/L) 0.16; Mean (nmol/L);
CEDIA 1.56; RIA 1.527; Correlation Coefficient 0.94;
y = 0.92x + 0.16; n = 52.
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Figure 24: Correlation between digozin assayed by RIA and EMIT.
RIA Assay Concentration (nmol/L)
Slope 1.008; Intercept (nmol/L) 0.009; Mean (nmol/L); 
EMIT 1.53; RIA 1.527; Correlation Coefficient 0.995; 
y = 1.998x + 0.009; n = 52.
1 8 0
7 . 8 .  STABILITY OF DIGOXIN IN SERUM AND PLASMA AT -20°C, 4°C AND ROOM
TEMPERATURE:
Figures 25 and 26 show the stabilities of digoxin in plasma and serum 
over a period of 18 days. The EMIT method gave very good digoxin 
stability for plasma and serum at the three temperatures studied. 
The CEDIA showed excellent stability for serum but variable digoxin 
was noted for the plasma. Significant instability occured during the 
first eight days, e.g. a drop of 41% was recorded from day 2 to day 4 
at -20°C.
The addition of heparin to the serum samples did not appear to have 
any effect (Table 56) . Some of the plasma digoxin results were
variable relative to those of the serum.
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F i g u r e  2 5 :  S t a b i l i t y  o f  D i g o x l n  i n  s e r u m  f o r  EMIT a s s a y .
DAYS
Figure 26: S ta b ility  of Digoxin In plasma for EMIT assay.
• Room Temperature 
■ -20°C
1 8 2
F i g u r e  2 7 :  S t a b i l i t y  o f  D i g o x i n  i n  s e r u m  f o r  C E D IA  a s s a y ,
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Figure 28: S ta b ility  of Digoxin in plasma for CEDIA assay.
Xo00
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and plasma from eleven patients on dlgoxln
T a b l e  5 6 :  T h e  e f f e c t  o f  h e p a r i n  o n  t h e  GEDIA I m m u n o a s s a y  u s i n g  s e r a
Patient Serum Dlgoxln 
Cone. 
(nmol/L)
Heparinised 
Plasma Dlgoxln 
Cone. 
(nmol/L)
Serum + Heparin 
Dlgoxln Cone. 
(nmol/L)
A 0.4 0.35 0.45
B 0.75 0.24 0.62
C 0.4 0.5 0.475
D 1.325 1.0 0.186
E 0.925 1.05 1.85
F 0.72 0.86 0.80
G 0.67 0.70
H 2.88 2.85
I 1.73 1.66
J 0.44 0.38
K 1.46 1.38
Simultaneous heparinised plasma and serum was taken from 6 patients 
namely, A, B, C, D, E and F.
*
1 8 4
7.9.1. Imprecision Studies:
The within batch and total imprecision performances of the EMIT and 
CEDIA assays follow:
(a) CEDIA Method:
7 . 9 .  SALIVARY DIGOXIN MEASUREMENT:
Within Batch Total
Gilford Level I: Mean = 1.85 nmol/L Mean = 2.03 nmol/L
SD = 0.07 nmol/L SD = 0.085 nmol/L
CV = 3.8% CV = 4.2%
Gilford Level II: Mean =3.28 nmol/L Mean =3.39 nmol/L
SD = 0.134 nmol/L SD = 0.152 nmol/L
CV = 4.1% CV = 4.5%
Gilford Level III: Mean =4.26 nmol/L Mean = 4 . 5  nmol/1
SD = 0.187 nmol/L SD = 0.21 nmol/L
CV = 4.4% CV = 4.7%
Number of estimates = 15.
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( b )  EMIT A s s a y :
Gilford Level I: Mean — 0.89 nmol/L 
SD = 0.33 nmol/L 
CV = 3.7%
W i t h i n  B a t c h
Mean - 0.96 nmol/L 
SD = .038 nmol/L 
CV - 4.0%
T o t a l
Gilford Level II: Mean =1 . 6  nmol/L 
SD = 0.061 nmol/L
CV = 3.8%
Mean = 1.71 nmol/L 
SD - 0.072 nmol/L 
CV = 4.2%
Gilford Level III: Mean =2.12 nmol/L 
SD = 0.085 nmol/L 
CV = 4.0%
Mean = 2.28 nmol/1 
SD = 0.10 nmol/L 
CV = 4.5%
Number of estimates = 15.
Digoxin concentration values for EMIT are approximately half that for 
CEDIA because the Gilford controls were diluted with equal volumes of 
saliva and serum. The parameter listing for the EMIT on the Cobas 
Bio, unlike that for the CEDIA, would not accept the 100% increase in 
sample volume.
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7.9,2. Sensitivity;
T a b l e  5 7 :  R e s u l t s  o f  1 0  r e p l i c a t e s  o f  t h e  z e r o  c a l i b r a t o r  s o l u t i o n .
EMIT CEDIA
Digoxin (nmol/L)Digoxin (nmol/L)
Mean 0.231 0.242
SD 0.036 0.042
Detection Limits (mean + 2.5 SD) 0.32 0.34
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7 . 9 . 3 .  Analytical Range :
The EMIT method Is linear from 0.32 to 5.12 nmol/L and the CEDIA 
method has an assay range from 0.34 to 5.12 nmol/L. Figure 29 show 
salivary calibration curve for CEDIA method. The salivary 
calibration curve for EMIT was similar to that for serum (Figure 14).
7.9.4. Recovery:
Table 58: Results of 5 replicates of 0.5, 1.0, 2.0, 3.0, 4.0 and 5
nmol/L of spiked digoxin saliva solutions.
Digoxin conc. % RECOVERY
(nmol/1) EMIT CEDIA
0.5 95 (5.1) 96 (5.0)
1.0 96 (3.9) 95 (3.8)
2.0 103 (3.7) 97 (3.9)
3.0 98 (4.1) 104 (4.3)
4.0 102 (3.9) 97 (4.4)
5.0 103 (4.3) 104 (4.2)
Shown in parenthesis is the coefficient of variation.
1 8 8
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the CEDIA immunoassay method.
F i g u r e  2 9 :  C a l i b r a t i o n  c u r v e  f o r  s a l i v a r y  d i g o x i n  m e a s u r e m e n t  u s i n g
Digoxin Concentration (ntnol/L)
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Figure 30 shows salivary DLIF cross-reactivity as "apparent digoxin" 
in both assays.
In renal failure, the EMIT method detected no DLIF in 16 samples. The 
remaining 4 samples were within the range 0.08-0.18 nmol/L. In the 
CEDIA method, 7 samples showed values up to 0.22 nmol/L.
7.9.5. Cross-Reactivity of DLIFs in Saliva:
Digoxin-free saliva from patients in renal failure, liver disease and 
third trimester pregnancy was tested for DLIF interference using the 
EMIT and CEDIA methods. These groups were selected since they are 
widely reported as having significant serum DLIF concentrations that 
interference with most digoxin immunoassays. DLIF concentration was 
measured as "apparent digoxin" in each group.
(a) Renal Disease:
Table 59: Salivary DLIF values determined as "apparent digoxin" in
renal disease (n=20).
Serum Creatinine 
(^mol/L)
"Apparent Digoxin" 
(nmol/L)
CEDIA EMIT
Mean 665 0.05 0.026
SD 382 0.076 0.055
Range (min-max) 134-1609 0.0-0.22 0.0-0.18
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(b) Liver Disease:
disease.
T a b l e  6 0 :  S a l i v a r y  D L IF  d e t e r m i n e d  a s  " a p p a r e n t  d i g o x i n "  i n  l i v e r
Serum Bilirubin 
(/jmol/L)
"Apparent Digoxin" 
(/imol/L)
CEDIA EMIT
Mean 70 0.045 0.03
SD 26 0.072 0.057
Range (min-max) 18-146 0.0-0.23 0.0-0.17
There was no DLIF detection in 75% and 65% of the samples in the EMIT 
and CEDIA methods, respectively. The remainder of the samples were 
outside the sensitivity range of both methods.
Figure 31 shows salivary DLIF cross-reactivity as "apparent digoxin" 
in both assays.
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Figure 30: Salivary DLIFa In renal disease.
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Figure 31: Salivary DLIFa In liv e r  disease.
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(c) Third Trimester Pregnancy:
trimester pregnancy (n=12).
T a b l e  6 1 :  S a l i v a r y  D L IF  d e t e r m i n e d  a s  " a p p a r e n t  d i g o x i n "  I n  t h i r d
"Apparent Digoxin" Cone. 
(nmol/L)
CEDIA EMIT
Mean 0.03 0.012
SD 0.045 0.029
Range (min-max) 0.0-0.1 0.0-0.09
In the EMIT method 83% of the salivary samples had no DLIF detected 
with negligible concentrations in the other samples, The CEDIA had 
66.6% of the samples showing no DLIF concentration and the remaining 
samples were beyond the sensitivity of the method.
Salivary DLIF are presented as "apparent digoxin" in Figure 32.
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F i g u r e  3 2 :  S a l i v a r y  D L IF s  i n  P r e g n a n c y
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•- "Apparent Digoxin Concentration" for each patient sample.
7 . 9 . 6 .  Serum/Saliva Ratio of Digoxin for the CEDIA and EMIT Methods:
The relationship between saliva and serum concentrations of digoxin 
for both methods is shown in Figures 33 and 34. The values for 
paired salivary and serum specimens were related by the following 
linear regression equations (based on y = mx + c).
CEDIA: Salivary Digoxin — 0.61 (Serum Digoxin) - 0.04
EMIT: Salivary Digoxin = 0.67 (Serum Digoxin) + 0
The mean saliva/serum concentration ratio (Table 62) is:
CEDIA: 0.62 with a standard deviation of 0.1
EMIT: 0.67 with a standard deviation of 0.1
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Figure 33: Correlation between salivary and serum Dlgoxin levels
using the modified Cedia method.
Serum Digoxin c o n c e n t r a t i o n  (nmol /I.)
Slope 0 . 6 1 ;  I n t e r c e p t  (ntnol/L) -  0 .0 4 ;  Mean (n mol /L) ;
Serum 1.66;  S a l i v a  0 .9 7 ;  C o r r e l a t i o n  C o e f f i c i e n t  0 . 9 4 ;
n = 20; y = 0 . 6 1x -  0 . 0 4 .
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using the EMIT method.
F i g u r e  3 4 :  C o r r e l a t i o n  b e t w e e n  s a l i v a r y  a n d  s e r u m  D i g o x i n  l e v e l s
Serum Digoxin  c o n c e n t r a t i o n  (nmol /L)
Slope 0 . 6 7 ;  I n t e r c e p t  (nmol/L) 0; Mean (nmol /L) ;
Serum 1.t>2; S a l i v a  1.09;  C o r r e l a t i o n  C o e f f i c i e n t  0 . 9 7 ;
n = 20;  y = 0 .67x + 0.
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7 . 9 . 7 .  Relationship between Free and Bound Digoxin in Serum:
Table 62: The following were the resu lts obtained from 8 normal
patients on digoxin.
Free Serum 
Digoxin 
(nmol/L)
Total Serum 
Digoxin 
(nmol/L)
Free Digoxin/Total Digoxin 
Ratio 
%
1.06 1.52 0.70
0.82 1.12 0.73
1.61 2.14 0.75
1.07 1.41 0.76
0.57 0.85 0.67
0.45 0.71 0.63
2.5 3.52 0.71
2.04 2.88 0.70
The mean saliva/serum ratio is 0.71 ± 0.04 (S.D.).
*
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C h a p te r  8
DISCUSSION
The narrow therapeutic range for digoxin makes it one of the more 
difficult drugs to administer even in patients with normal renal 
function. Different immunoassays give different responses to 
interfering substances. It is important, therefore, that an accurate 
method for digoxin monitoring is available, and with this in mind, 
the CEDIA and EMIT methods were evaluated in terms of imprecision, 
sensitivity, analytical range, curve stability, accuracy and 
interference.
IMPRECISION:
The coefficients of variation obtained for the EMIT assay are better 
than those reported by Syva in their technical information sheet for 
the Cobas Bio [73]. Their data show increased imprecision at normal 
and high digoxin concentration with within batch CVs of 4.3% at 2.54 
nmol/L and 5.9% at 3.29 ranol/L. A mean within batch CV of 3.5% was 
found in this study in the range of 1.85 to 4.4 nmol/L digoxin. The 
total imprecision was found to be approximately 4.6% compared to 5% 
for the manufacturer over the range 2.51 to 3.58 nmol/L digoxin.
The CEDIA assay was found to be precise also and gave CVs which were 
similar to those for EMIT. The results compared well with those 
reported by Jacobs [108].
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The good precision may be related to the stability of the reagents on 
storage and to features of the Cobas Bio such as a digitally- 
controlled syringe pipetting system, closed sample vials, photometric 
system, longitudinal cuvette arrangement and excellent temperature 
regulation. The total precision also confirms the stability and 
suitability of the quality control materials used.
SENSITIVITY AND ANALYTICAL RANGE:
The CEDIA calibration curve was linear from 0.0 to 5.12 nmol/L as 
illustrated in Figure 15. The linear response occurs because the 
amount of enzyme activity present is directly proportional to the 
amount of digoxin. Samples with reaction rates greater than that for 
5.12 nmol/L require a predilution step using the zero digoxin 
calibrator. An average rate change of 28 mA per 1.28 nmol/L was 
observed. The sensitivity was found to be 0.3 nmol/L which compares 
well with the 0.2 ng/ml (.26 nmol/L) quoted in the kit insert.
The calibration curve for the EMIT method was non-linear because with 
increasing digoxin concentration, the glucose-6-phosphate
dehydrogenase reacts with digoxin in a logarithmic manner. The kit 
insert gives the assay range as 0.64-5.12 nmol/L. This study showed 
that the Cobas Bio can distinguish between digoxin concentrations up 
to 6.0 nmol/L. This obviates the need for sample predilution and 
repeat measurement, hence faster turn-around time for samples with 
digoxin concentrations of approximately 6.0 nmol/L. However, the 
precision of values outside the assay range was not assessed.
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The sensitivity of the EMIT method was 0.28 nmol/L which was better 
than that for the CEDIA. The higher value was probably matrix 
related. The information relating to the good sensitivity achieved 
here would be very useful in the analysis of specimens with digoxin 
concentrations less than the assay range. Calibrators could be 
diluted to extend the range.
ACCURACY:
This was assessed by the method of addition. The two methods are 
almost identical in terms of accuracy with recoveries of 96-102%. 
The CVs for the recovery studies did not exceed 4% and generally 
compared well with the imprecision of the assays. The CEDIA 
literature report recoveries of 100% at 2.14 nmol/L, 97% at 2.56 
nmol/L and 98% at 3.08 nmol/L [108]. No further recovery evaluations 
for either method could be found.
CALIBRATION CURVE STABILITY:
As reagents deteriorate over time, it is necessary to determine 
stability, thus minimizing expenditure on reagents and calibrators 
and ensuring adequate assay performance. In this study, both assays 
were calibrated on day zero after which calibrators were treated as 
samples. The results for both the EMIT and CEDIA methods were 
consistent for the first 12 days, thus allowing the analysis of a 
greater number of samples per batch (Figures 16-17). Suitable 
controls should be routinely used to assess curve stability.
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The "DENS" option on the Cobas Bio has a facility for assessing 
calibration curve stability based on analysing the zero calibrator 
only. Using absorbance readings from this standard, the slope and 
intercept are updated. This can be utilized on a daily basis once 
verified by appropriate controls. Significant savings can be made
for low volume assays in which large amounts of reagents are
consumed.
DLIF INTERFERENCE:
DLIFs continue to cause problems in digoxin immunoassays. The use of 
such assays which suffer from DLIF interference for digoxin 
monitoring can indicate "apparent digoxin concentrations" greater
than the therapeutic range for exogenous digoxin leading to errors in 
measurement and clinical interpretation. These limitations suggest 
that each assay and antibody lot should be evaluated for DLIF
interference and a selective assay chosen to discriminate between
these endogenous factors and digoxin.
In this study, two methods were compared for their ability to
eliminate DLIF interference. The CEDIA assay required no pre­
treatment of the serum sample, thus relying exclusively on the 
specificity of the antibody. No previous evaluations of DLIF
interference in the CEDIA immunoassay could be found. In the EMIT 
method, the sample extraction step is used to remove protein and 
other substances that might interfere. The EMIT method appears to 
eliminates or reduces DLIF interference in the groups of patients 
mentioned (Figures 18-21).
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From the results obtained, certain observations were made. The data 
confirms the presence of significant amounts of DLIF in the clinical 
groups studied. The concentration was dependent on the immunoassay 
used. The greatest concentrations were measured by the CEDIA method 
having 55% of its DLIF values within the range of 0.5-1.18 nmol/L of 
"apparent digoxin" compared with a range of 0-0.35 nmol/L for all of 
the samples using the EMIT method. For the CEDIA method, only 11.8% 
of the samples showed no detectable levels of DLIF as against 68.6% 
for the EMIT. The remaining DLIFs were below the detection limits 
for the EMIT (i.e. 0.28 nmol/L). Some researchers have omitted these 
lower detection limits from their work and others have linked their 
results to sera with no detectable DLIFs.
Valdes [92] reports that DLIF is present in three forms in the serum, 
tightly protein bound, weakly bound and free. More than 90% of DLIFs 
is lightly but reversibly bound in serum of normal people. In 
pregnant women, neonates and renal failure, an increase in the weakly 
bound fraction occurs rather than an increased total DLIF. The 
increase in the weakly bound fraction makes the DLIF more available 
to the immunoassay antibody resulting in increased DLIF 
concentration. The hydrophobic column pre-assay separation step used 
in EMIT, separated the weakly protein-bound DLIF from the serum. 
This protein separation method does not appear to disrupt protein 
bound DLIF.
It is postulated that DLIFs cross-react with antibodies due to 
structural similarities with the drugs. It has been suggested that 
if the same biological response is produced by DLIF and the drug, 
they may react at the same receptor sites. This structural
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similarity at the epitope would then lead to antibody 
cross -reactivity.
It has been shown that haemolysis, icterus, lipaemia and protein may 
affect the accuracy of many clinical chemistry analyses. For 
handling specimens with these potential interferents, the stated 
limitations of the procedure are often vague, e.g. Cedia insert "The 
use of grossly haemolysed, lipaemic, icteric specimens is not 
recommended". The knowledge of the type of bias and the 
concentration at which the interferent is detectable is important. 
With a proper analytical system, this data can be used to eliminate 
unnecessary repeat sampling associated with qualitative methods.
BILIRUBIN:
Bilirubin is present in the plasma in two forms; conjugated, which is 
the water soluble form, and unconjugated, which is transported bound 
to albumin. Although the presence of bilirubin conjugated to 
glucuronic acid has been recognised for some time, recent evidence 
indicates that bilirubin covalently bound to albumin can also be a 
significant contributor to jaundice. Bilirubin is known to interfere 
with a number of analytical methods, e.g. haemoglobin and cholesterol 
estimation. In this study, the effect of bilirubin on the CEDIA and 
EMIT assay was investigated.
Bilirubin did not interfere with the EMIT method, (Tables 42-44). The 
column chromatography pre-treatment step successfully removed 
bilirubin and other interferents, thus ensuring specificity of the 
assay.
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In the CEDIA assay, the pooled serum studied showed falsely low 
digoxin recoveries at bilirubin concentrations greater than 46.8 
pmol/1 approximately, with total loss of recovery at 140.4 /¿mol/L, 
(Tables 42-44). This may explain the low concentration of DLIF found 
in liver disease (Table 38). It may also account for the DLIF 
concentration pattern found in the correlations study which 
investigated the relationship between liver disease and DLIF 
concentration (Table 41).
It is not clear how bilirubin interferes with the assay. It may be 
that elevated levels of other chemicals due to liver disease cause 
the interference. Another reason it interferes may be due to the 
similarity between the colour of bilirubin and that of the substrate 
product which is yellow. The initial absorbance reading produced is 
proportional to the bilirubin concentration. In the Cobas Bio 
absorbance rates for the samples are calculated by subtracting the 
lower from the higher absorbance readings (Section 5.3.5.). In 
icteric samples, the absorbance changes recorded are small. This is 
because the combined absorbance readings of the bilirubin and 
substrate product exceed the absorbance capability of the spectro­
photometer.
LIPIDS:
In recent studies it has been shown that fatty acids cross-react 
with digoxin antibodies. This particular study examined the 
interference caused by lipaemia on the two methods using a pooled 
sample and three lipaemic samples A, B and C.
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No lipid interference was encountered in the EMIT method (Tables 
45-47). This was due to the extraction of lipid and protein from 
serum digoxin In the pre-treatment step.
In the CEDIA assay inhibition of digoxin recovery occured (Tables 
45-47). The concentration of cholesterol and triglyceride at which 
the interference occured was highly variable in the three patients 
and pooled sera studied. Both appear to contribute to the low 
digoxin recoveries.
Murty et al [109] reported one severly lipaemic sample giving a 
digoxin concentration 30% lower than that from an RIA method. From 
my study it is evident that qualitative terms such as "severly 
lipaemic" is inadequate to describe CEDIA assay limitations. For 
example, patient A with cholesterol concentrations of 6.4 mmol/L and 
triglyceride concentrations of 5.8 mmol/L caused inhibition but still 
cannot be classified as severely lipaemic (Table 48). Consequently, 
serum triglyceride and cholesterol concentrations are required to 
define the degree of interference with lipids.
In the CEDIA assay, falsely low digoxin values may result from 
cholesterol and triglyceride blocking the binding sites on the EA 
molecule. This inhibits complementation of EA and ED when the ED 
molecule is added to the reaction mixture, i.e. inhibition of f)- 
galactosidase formation. Another problem encountered with lipaemic 
samples is the change in viscosity resulting in poor sampling 
precision due to the high concentration of triglyceride.
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HAEMOLYSIS:
The influence of haemolysis on serum digoxin was evaluated using both 
methods (Tables 49-51). Haemolysis did not interfere with EMIT due 
to the removal of haemoglobin along with other proteins from digoxin 
in serum samples by the pre-treatment step.
In the CEDIA method, the presence of haemoglobin exceeding 70 mg/dl 
caused falsely reduced results and concentrations greater than 266 
mg/dl resulted in zero percentage recovery of the 2, 3 and 4 nmol/L 
digoxin solutions.
In the second study involving paired haemolysed and non-haemolysed 
samples from each of eight patients on digoxin, the non-haemolysed 
sera showed comparable results for both methods. The presence of 
haemolysis in the sera caused no interference with the EMIT but total 
inhibition of digoxin recovery with the CEDIA (Table 52).
These results for the CEDIA reject those by Multy et al. who reported 
that haemolysis had no effect. No information was given on the 
haemoglobin concentration or the procedure used by him. My study 
showed that haemoglobin concentrations of 80.5 mg/dl gave reductions 
of 14% approximtely in digoxin with no recovery of digoxin at 266 
mg/dl. The use of "haemolysis" in such vague terms as that used by 
Multy et al can be very misleading and may have serious clinical 
consequences.
A  sample that contains haemoglobin with a concentration greater than 
70 mg/dl will inhibit digoxin recovery. This occurs because the
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methaemoglobin present in the haemolysed sample exhibits its maximum 
absorbance in the Sor6t band region 400-440 nm. Since the CEDIA 
method uses a wavelength of 420 nm for digoxin measurement, spectral 
interference occurs. The initial absorbance reading is proportional 
to the methaemoglobin concentration. In grossly haemolysed sera 
(Table 52) the initial absorbance reading was so high that it 
exceeded the linearity of the method and thus "flagged" "high 
absorbance". In specimens with haemoglobin concentrations of, for 
example, 91 mg/dl the absorbance changes recorded were small. This 
occured because the combined absorbance values of the methaemoglobin 
and substrate product were outside the absorbance capability of the 
spectrophotometer.
PROTEIN:
Burnett et al. using an RIA method suggested that the determined 
digoxin concentrations are, to a certain extent, related to albumin 
concentrations [110]. This effect of albumin on the value for 
digoxin has been investigated in this study using both methods.
The EMIT method was not affected by albumin because the hydrophobic 
column used in the extraction step separated the albumin from the 
serum digoxin (Tables 53-55). As a result of this, the method is not 
sensitive to changes in albumin concentration.
For the CEDIA method the determined digoxin concentration was falsely 
high at low albumin concentrations (less than 40 g/1) (Tables 53-55). 
The data suggests that with increasing albumin concentration within 
the range 0-40 g/1 approximately, there was an apparent decrease in
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digoxin concentration. However, Holtzman et al. suggests that 
albumin increases the binding of radiolabel to antibody, an apparent 
contradiction to my findings [106]. This apparent difference is 
explained by the type of separation method used. In his study, 
Holtzman used charcoal to adsorb the free digoxin and assayed the 
albumin with the antibody-digoxin complex. Thus, when the albumin is 
in solution with the antibody, an apparent increase in the digoxin 
binding to albumin is observed due to the radiolabel combining with 
albumin and antibody. On the contrary, when the digoxin-antibody 
complex is separated from albumin there is a decrease in the apparent 
digoxin concentration.
The exact mechanism by which albumin i.e. less than 40 g/1
approximately, interferes with digoxin measurement is unclear. The 
data acquired in this study may be partly explained by the fact that 
25% approximately of serum digoxin is bound to albumin, and as 
albumin decreases more digoxin is present in the free state. The 
unbound digoxin is free to react with the antibody, thus resulting in 
increased /3-galactosidase formation and activity. While the data 
suggests that the CEDIA assay is sensitive to albumin concentration, 
this is insufficient to explain the large discrepancies in digoxin 
concentration encountered. It is also extremely unlikely that low 
affinity of the antibody was responsible due to the adequate 
sensitivity of the method. Drug interference can also be eliminated. 
As already shown, the lack of specificity of the antibody in the 
CEDIA assay may be a factor.
At high albumin concentration i.e. greater than 79 g/1 approximately, 
decreased recovery of digoxin was observed using the CEDIA method.
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Falsely elevated results due to hypoalbuminemia can be corrected by 
adding 40 g/1 of albumin to the analyte solution. Pseudo-
hypodigoxinemia can be rectified by adding an appropriate volume of 
isotonic saline to the specimen [111].
In this study, it has been shown that haemolysis, lipaemia, proteins 
and icterus interfere with the CEDIA method. The use of qualitative 
terms when describing interference should be avoided because it is 
difficult to accurately distinguish between various concentrations of 
lipaemia, haemolysis or icterus. The inaccurate results attributable 
to these interferences can be avoided through the development of 
accurate electronic methods which have the ability to identify and 
reject such samples, or preferably, the development of a pre-
treatment step such as that used in the EMIT technique.
METHOD COMPARISON:
Plots of the comparison between the EMIT, CEDIA and external
laboratory RIA, with regression analysis data are shown in ( Figures 
22-24). The agreement between EMIT and RIA methods for analysis of 
patient samples was considered suitable for routine use. However, 
there were statistically significant differences between these and 
the CEDIA. The largest difference was between the CEDIA and RIA 
methods.
When the RIA and EMIT were compared with CEDIA, the slopes were less 
than 0.93, indicating that the EMIT and RIA values tended to be lower 
than the CEDIA values. Comparison of RIA and EMIT showed an
This decrease was due to the dilutional effect of the albumin.
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intercept of almost zero but when compared with CEDIA, a positive 
intercept of approximately 0.16 nmol/L was observed. When the mean 
values of EMIT and RIA were compared with CEDIA, a negative bias 
similar to that of the intercept was demonstrated. The higher mean 
value for CEDIA is probably attributable to the presence of 
endogenous DLIF in some of the samples augmenting the digoxin 
results. This supports the assessment already made that DLIF had no 
effect on the measured digoxin in serum from renal or liver disease, 
third trimester pregnant women and neonates when using the EMIT 
assay. This, once again, demonstrates the unsuitability of the CEDIA 
method for measuring such samples.
STABILITY OF DIGOXIN IN SERUM AND PLASMA:
(Figures 25-28) show that digoxin is stable in serum and plasma for 
up to 18 days when stored at -20°C, room temperature and 4°C using 
the EMIT method. Serum digoxin was stable for 18 days using the CEDIA 
method while plasma digoxin was quite unstable. When stored at 4°C, 
for example, it showed an increase of +48% approximately at day 5, 
decreasing to -6% on day 12, and increasing to 48% again on day 18. 
In view of the good stability of digoxin in serum, it is clear that 
plasma is unsuitable for digoxin estimation using the CEDIA method.
In this study, heparanised plasma samples were used. In their study, 
Stromme et al. described how heparin interfered with the methodology 
for creatine kinase [112]. Heparin reacts with several plasma 
proteins forming heparin-protein complexes. The precipitation of 
this complex is dependent on the pH and inorganic ions present in the 
assay solution. For this reason, he suggests that heparinised plasma
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may not be suitable for enzyme assays. However, my study involving 
eleven patients' sera showed that heparin, when added to these 
samples, did not interfere with the CEDIA immunoassay. In the 
heparinised plasma samples some results varied from those of the 
serum. However, a larger study is required to validate this and if 
proven, fibrinogen or the clotting factors, should be investigated as 
the possible cause of these variable results.
SALIVARY DIGOXIN:
The manner in which therapeutic drugs enter saliva is well documented 
[80] . Transfer of digoxin, which is a non-ionized, relatively fat 
soluble, neutral drug into saliva appears to be passive and the 
salivary digoxin level should correlate with the free-digoxin 
(unbound) in plasma. Salivary sampling is a non-invasive technique, 
suitable for small children, aged people or where repeated sampling 
is required. Where appropriate, it can eliminate costs associated 
with hospitalization and phlebotomy.
In this study, the EMIT and CEDIA kits have been successfully used 
for salivary digoxin measurement. In adapting the EMIT kit, no 
procedural modifications were required and the saliva was treated 
similarly to serum. This was made possible by the pre-assay 
extraction step which eliminated the incidence of spurious and non- 
reproducible digoxin results found in direct RIA procedures [80].
In the adaptation of the CEDIA method, equal volumes of albumin 
diluent (conc. 80 g/1) were added to saliva samples in order to 
equalize the protein concentration in saliva and serum. Saliva has
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low protein concentration of 1-4 g/ 1 . The effect of this low protein 
concentration has already been demonstrated (Section 7.6.5.)- The 
sample volume was increased from 25 to 50 /xl to compensate for the 
sample dilution.
In the standard curve plot, (Figure 29), the absorbances for the 
CEDIA salivary modification were lower than those for the serum 
digoxin. This was probably attributable to the dilutional effect due 
to increased sample volume. The precision, sensitivity and 
recoveries for salivary digoxin were comparable to those reported for 
serum digoxin (Tables 57-58 and Section 7.9.1.).
The EMIT method showed a good linear relationship between digoxin 
concentrations in serum and saliva with a mean ratio of saliva to 
serum digoxin of 0.67 with a standard deviation of 0.1 (Figure 34). 
The CEDIA method had a lower saliva/:serum ratio (0.62) (Figure 33). 
This was probably due to the viscosity of some of the saliva samples 
causing decreased sample aspiration by the Cobas Bio and hence, lower 
results.
Equilibrium dialysis showed that the fraction of free drug in saliva 
was 0.71 (Table 62), which compares favourably with that for EMIT. 
As this fraction of the total serum digoxin is free, it appears that 
it is in equilibrium with saliva. The saliva/serum ratios for EMIT 
and CEDIA are lower, compared with the values of 1.7, 1.14 and 1.27 
reported by other workers [81,82,84]. A number of explanations for 
ratio differences have been proposed, including specificity of 
digoxin antibody used and saliva enzymes. Patients with heart 
failure have impaired parasympathetic function which is independent
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of that associated with digoxin therapy. This may alter the 
composition of saliva. Varability in saliva/serum ratios have been 
reduced in one study by increasing saliva flow [81]. However, in 
other studies, the salivary digoxin was found to be independent of 
flow [80]. Another reason for discrepant results may be due to 
improper sampling procedure. In the early stages of my study, 
samples from twelve patients when analysed gave saliva/serum ratios 
as high as 1.64. This was caused by paired saliva/serum samples not 
being taken simultaneously.
Using both methods, apparent DLIF concentrations exceeding the 
sensitivity were shown and because of this, it was difficult to 
assess their significance (Tables 59-60). However, this may reflect 
the salivary fraction which is in equilibrium with the 10% 
approximation of free serum DLIF. The apparent lack of DLIF in 
saliva renders it more appropriate than serum for use in 
immunoassays having non-specific digoxin antibodies.
From this investigation, it is evident that the discrepancies 
reported by various workers may be attributable to unreliable 
methodology. This was evident in the CEDIA where salivary matrix 
interfered. This effect was eliminated in the EMIT through the use 
of an extraction step, thus rendering it suitable for salivary 
digoxin measurement. The determination of salivary digoxin
concentration appears to be an alternative to blood sampling with 
good reproducibility, accuracy and correlation with serum 
concentration.
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CONCLUSION
This study provides further evidence of the lack of specificity in 
some present-day digoxin immunoassays. Matrix effects associated 
with variations in protein as well as interference by DLIFs, 
lipaemia, haemolysis, bilirubin and anticoagulants used, have been 
observed in the CEDIA method. THe use of hydrophobic chromatography 
greatly reduced or eliminated similar interference in the EMIT. The 
EMIT was also successfully used for salivary digoxin estimation. The 
saliva/serum ratio was comparable to that obtained by the equilibrium 
dialysis method but that for the CEDIA was lower due to the matrix 
effect, i.e. increased saliva viscosity.
The EMIT method is a simple, widely applicable specific method for 
digoxin estimation. Its use is very appropriate in certain clinical 
groups where DLIF values are high, such as in patients with renal and 
hepatic failure, pregnancy and neonates. The EMIT method is the most 
suitable for measuring serum and salivary digoxin.
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